"Acanthamoeba Keratitis: Dose Response Models",1,"CDC. (2012). ""Parasites- Acanthamoeba.""   Retrieved 03/30/2012, 2012, from http://www.cdc.gov/parasites/acanthamoeba/."
"Acanthamoeba spp: Dose Response Models",1,"CDC. (2012). ""Parasites- Acanthamoeba.""   Retrieved 03/30/2012, 2012, from http://www.cdc.gov/parasites/acanthamoeba/. "
"Acanthamoeba spp: Dose Response Models",2,"Culbertson, C. G., P. W. Ensminger, et al. (1966). ""Hatmanella (Acanthamoeba). Experimental Chronic Granulomatuous Brain Infection Produced by New Isolates of Low Virulence."" The American Journal of Clinical Pathology 46(3): 305-314"
Adenovirus,1,"[http://en.wikipedia.org/wiki/Adenoviridae Wiki]"
Adenovirus,3,"Hierholzer J. (1992) Adenoviruses in the Immunocompromised Host. Clinical Microbiology Reviews. 5(3): 262-274. [http://cmr.asm.org/cgi/reprint/5/3/262 Full Text]"
Adenovirus,4,"Lee J, Choi E, and Lee H. (2010) Clinical severity of respiratory adenoviral infection by serotypes in Korean children over 17 consecutive years (1991-2007). Journal of Clinical Virology. 49: 115-120. [http://www.sciencedirect.com.proxy2.cl.msu.edu/science/article/pii/S138665321000274X Full Text] "
Adenovirus,5,"Rosete D, Manjarrez M, and Barron B. (2008) Adenoviruses C in non-hospitalized Mexican children older than five years of age with acute respiratory infection. 103(2): 195-200. [http://www-ncbi-nlm-nih-gov.proxy2.cl.msu.edu/sites/entrez?Db=pubmed&Cmd=Retrieve&list_uids=18425273&dopt=abstractplus Abstract]"
Adenovirus,6," CDC http://www.cdc.gov/adenovirus/index.html "
"Adenovirus Exposure Assessment",1,[http://www.cdc.gov/adenovirus/about/overview.html]
"Adenovirus Exposure Assessment",2,"[http://en.wikipedia.org/wiki/Adenoviridae Wiki]"
"Bacillus anthracis",1,"[http://www.springerlink.com.proxy2.cl.msu.edu/content/136q4u1j54743815/fulltext.pdf Int Care Med]"
"Bacillus anthracis",3,"[http://www.bt.cdc.gov/agent/anthrax/ CDC]"
"Bacillus anthracis",7,"Holty J, Bravata D, Liu H, Olshen R, Mcdonald K, and Owens D. (2006) Systematic Review: A Century of Inhalational Anthrax Cases from 1900 to 2005. Annals of Internal Medicine. 144, 4. 270-280. [http://www.annals.org/content/144/4/270 Full Text]"
"Bacillus anthracis",8,"Bravata D, Holty J, Wang E, Lewis R, Wise P, McDonald K, and Owen D. (2007) Inhalational, Gastrointestinal, and Cutaneous Anthrax in Children. Arch Pediatr Adolesc Med. 161 (9): 896-905.  [http://archpedi.ama-assn.org/cgi/reprint/161/9/896.pdf Full Text]"
"Bacillus anthracis",14,"Kaya A, Tasyaran M, Erol S, Ozkurt Z, and Ozkan B. (2002) Anthrax in Adults and Children: A Review of 132 Cases in Turkey. Eur J Clin Microbiol Infect Dis. 21: 258-261. [http://www.springerlink.com/content/v8ctc3ajmnwxhryn/fulltext.pdf Full Text]"
"Bacillus anthracis",19,"Brookmeyer, R., Johnson, E., & Barry, S. (2005). Modelling the incubation period of anthrax. Statistics in Medicine, 24(4), 531â542. doi:10.1002/sim. [http://www.ncbi.nlm.nih.gov/pubmed/15678407 Full Text]"
"Bacillus anthracis: Dose Response Models",1,"Centers for Disease Control and Prevention (CDC) (2003) Emergency Preparedness and Response: Anthrax Q&A Signs and Symptoms [http://www.bt.cdc.gov/agent/anthrax/faq/signs.asp]"
"Bacillus anthracis: Dose Response Models",2,"Guidi-Rontani, C., Weber-Levy, M. Labruyere, E., Mock, M. (1999) Germination of ''Bacillus anthracis'' Spores Within Alveolar Macrophages. ''Molecular Microbiology'' '''31'''(1):9-17 [http://www.sciencedirect.com/science/article/pii/S0966842X02024228] "
"Bacillus anthracis: Dose Response Models",3,"Jernigan, J.A., Stephens, D.S., Ashford, D.A., Omenaca, C., Topiel, M.S>, Galbraith, M., Tapper, M., Zaki, S., Popovic, T., Meyer, R.F., Quinn, C.P., Harper, S.A., Fridkin, S.K., Sejvar, J.J., Shepard, C.W., McConnell, M., Guarner, J., Sheith, W-J., Malecki, J.M., Gerberding, J.L., Hughes, J.M., Perkins, B.A. (2001). Bioterrorism Related Inhalational Anthrax: The First 10 Cases Reported in the United States. Emerging Infectious Diseases. '''7'''(6): 933-944 "
"Bacillus anthracis: Dose Response Models",4,"Druett HA, Henderson DW, Packman L, Peacock S (1953) Studies on respiratory infection. I. The influence of particle size on respiratory infection with anthrax spores. Journal of Hygiene. 51: 359-371  [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2217739/pdf/jhyg00161-0069.pdf Full Text PDF via NIH]"
"Bacillus anthracis: Dose Response Models",5,"Altboum Z, Gozes Y, Barnea A, Pass A, White M, Kobiler D (2002) Postexposure prophylaxis against anthrax: Evaluation of various treatment regimes in intranasally infected guinea pigs Infection and Immunity 70(1): 6231-6241 [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC130326/ Full Text via PubMed]"
"Bacillus anthracis: Dose Response Models",6," Weir, M.H. (2009) Development of a Physiologically Based Pathogen Transport and Kinetics Model for the Inhalation of ''Bacillus anthracis'' Spores. Ph.D. Dissertation. Drexel University, Philadelphia PA [http://wiki.camra.msu.edu/images/b/bf/WeirM_2009_Dissertation.pdf] "
"Bacillus anthracis: Dose Response Models",7,"Weir, M.H. and Haas, C.N. (2011) A Model for In-vivo Delivered Dose Estimation for Inhaled ''Bacillus anthracis'' Spores in Humans with Interspecies Extrapolations. Environmental Science and Technology. '''45'''(13): 5828-5833 [http://pubs.acs.org/doi/abs/10.1021/es200901e] "
"Bacillus anthracis: Dose Response Models",8,"Weir, M.H. and Haas, C.N. (2011) A Model for In-vivo Delivered Dose Estimation for Inhaled ''Bacillus anthracis'' Spores in Humans with Interspecies Extrapolations. Environmental Science and Technology. '''45'''(13): 5828-5833 [http://pubs.acs.org/doi/abs/10.1021/es200901e] "
"Brief example of a point-estimate risk characterization",1,"""Lodge et al. 2002""; need to locate & expand this incomplete reference"
"Brief example of a point-estimate risk characterization",2,"[[Cryptosporidium parvum and Cryptosporidium hominis: Dose Response Models]]"
"Brief example of a point-estimate risk characterization",3,"Haas CN, Rose JB and Gerba CP (1999) Quantitative Microbial Risk Assessment. New York, NY: John Wiley & Sons, Inc."
Burkholderia,1,"Muhammad RA Hassan, Subhada P Pani, Ng P Peng, Kirtanaa Voralu, Natesan Vijayalakshmi, Ranjith Mehanderkar, Norasmidar A Aziz, Edwin Michael. (2010) Incidence, risk factors and clinical epidemiology of melioidosis: a complex socio-ecological emerging infectious disease in the Alor Setar region of Kedah, Malaysia. BMC Infectious Diseases. 10:302. [http://www.biomedcentral.com.proxy2.cl.msu.edu/content/pdf/1471-2334-10-302.pdf Full Text]"
Burkholderia,2,"[http://en.wikipedia.org/wiki/Melioidosis Wikipedia]"
Burkholderia,4,"NAM SU KU , SANG HOON HAN , CHANG OH KIM , JI-HYEON BAEK , SU JIN JEONG , SUNG JOON JIN , JUN YONG CHOI , YOUNG GOO SONG & JUNE MYUNG KIM. (2011) Risk factors for mortality in patients with Burkholderia cepacia complex bacteraemia. Scandinavian Journal of Infectious Diseases, 43: 792â797 [http://informahealthcare.com.proxy2.cl.msu.edu/doi/pdf/10.3109/00365548.2011.589076 Full Text]"
Burkholderia,5,"Simpson, A. J. H., Suputtamongkol, Y., Smith, M. D., Angus, B. J., Rajanuwong, A., Wuthiekanun, V., Howe, P. A., et al. (1999). Comparison of Imipenem and Ceftazidime as Therapy for Severe Melioidosis. Clinical Infectious Diseases, 29(2), 381â387. doi:10.1086/520219 [http://cid.oxfordjournals.org.proxy1.cl.msu.edu/content/29/2/381.full.pdf+html Full Text]"
Burkholderia,6,"Currie, B., Howard, D., Nguyen, V. T., Withnall, K., & Merianos, A. (1993). The 1990-1991 outbreak of melioidosis in the Northern Territory of Australia: clinical aspects. The Southeast Asian journal of tropical medicine and public health, 24(3), 436â443. [http://www.ncbi.nlm.nih.gov/pubmed/8160049 Full Text]"
Burkholderia,7,"Currie, B. J., Fisher, D. A., Anstey, N. M., & Jacups, S. P. (2000). Melioidosis: acute and chronic disease, relapse and re-activation. Transactions of the Royal Society of Tropical Medicine and Hygiene, 94(3), 301â304. doi:10.1016/S0035-9203(00)90333-X [http://www.sciencedirect.com/science/article/pii/S003592030090333X Full Text]
"
Burkholderia,9,"Bhengsri, S., Baggett, H. C., Jorakate, P., Kaewpan, A., Prapasiri, P., Naorat, S., Thamthitiwat, S., et al. (2011). Incidence of Bacteremic Melioidosis in Eastern and Northeastern Thailand. The American Journal of Tropical Medicine and Hygiene, 85(1), 117â120. doi:10.4269/ajtmh.2011.11-0070 [http://www.ajtmh.org/content/85/1/117 Full Text]"
Burkholderia,13,"[http://www.cdc.gov/melioidosis/index.html CDC]"
"Campylobacter jejuni",1,"Ternhag, A., TÃ¶rner, A., Svensson, Ã., Giesecke, J., & Ekdahl, K. (2005). Mortality following Campylobacter infection: a registry-based linkage study. BMC Infectious Diseases, 5, 70. doi:10.1186/1471-2334-5-70 [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1236927/pdf/1471-2334-5-70.pdf Full Text]
"
"Campylobacter jejuni",3,"Helms, M., Vastrup, P., Gerner-Smidt, P., & MÃ¸lbak, K. (2003). Short and long term mortality associated with foodborne bacterial gastrointestinal infections: registry based study. BMJâ¯: British Medical Journal, 326(7385), 357. [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC148890/pdf/357.pdf Full Text]"
"Campylobacter jejuni",4,"[http://emedicine.medscape.com/article/213720-overview#showall Medscape Page]"
"Campylobacter jejuni",5,"[http://www.cdc.gov/nczved/divisions/dfbmd/diseases/campylobacter/ CDC Page]"
"Campylobacter jejuni",6,"Vital Signs: Incidence and Trends of Infection with Pathogens Transmitted Commonly Through Food --- Foodborne Diseases Active Surveillance Network, 10 U.S. Sites, 1996--2010. (n.d.). http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6022a5.htm?s_cid=mm6022a5_w"
"Campylobacter jejuni",7,"Ternhag, A., Asikainen, T., Giesecke, J., & Ekdahl, K. (2007). A Meta-Analysis on the Effects of Antibiotic Treatment on Duration of Symptoms Caused by Infection with Campylobacter Species. Clinical Infectious Diseases, 44(5), 696â700. doi:10.1086/509924 [http://cid.oxfordjournals.org/content/44/5/696.full.pdf+html Full Text]"
"Campylobacter jejuni",8,"Feodoroff B, Lauhio A, EllstrÃ¶m P and Rautelin H (2011) A Nationwide Study of Campylobacter jejuni and Campylobacter coli Bacteremia in Finland Over a 10-Year Period, 1998â2007, With Special Reference to Clinical Characteristics and Antimicrobial Susceptibility. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 53 (8), e99âe106."
"Campylobacter jejuni and Campylobacter coli: Dose Response Models",1,"Havelaar AH, Pelt W, Ang CW, Wagenaar JA, Putten JP, Gross U and Newell DG (2009) Immunity to ''Campylobacter'': its role in risk assessment and epidemiology. ''Critical Reviews in Microbiology''. 35 (1), 1-22. [http://informahealthcare.com/doi/abs/10.1080/10408410802636017?select23=Choose Full Text] "
"Campylobacter jejuni and Campylobacter coli: Dose Response Models",2,"Chen L, Geys H, Cawthraw S, Havelaar A and Teunis P (2006) Dose response for infectivity of several strains of ''Campylobacter jejuni'' in chickens. ''Risk Analysis''. 26 (6), 1613-1621.[http://onlinelibrary.wiley.com/doi/10.1111/j.1539-6924.2006.00850.x/pdf Full Text]"
"Campylobacter jejuni and Campylobacter coli: Dose Response Models",8,"Chen L, Geys H, Cawthraw S, Havelaar A and Teunis P (2006) Dose response for infectivity of several strains of Campylobacter jejuni in chickens. Risk Analysis: An Official Publication of the Society for Risk Analysis. 26 (6), 1613-1621."
"Campylobacter jejuni and Campylobacter coli: Dose Response Models",10,"Medema GJ, Teunis PF, Havelaar AH and Haas CN (1996) Assessment of the Dose-Response Relationship of Campylobacter jejuni. International Journal of Food Microbiology. 1 (2), 101-111."
"Campylobacter jejuni and Campylobacter coli: Dose Response Models",12,"Tribble DR, Baqar S, Carmolli MP, Porter C, Pierce KK, Sadigh K, Guerry P, Larsson CJ, Rockabrand D, Ventone CH et al (2009) Campylobacter jejuni strain CG8421: a refined model for the study of Campylobacteriosis and evaluation of Campylobacter vaccines in human subjects. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 49 (10), 1512-1519. [http://cat.inist.fr/?aModele=afficheN&cpsidt=22121873 Full Text]"
"Case Studies",1,"full citation"
"Case Studies",3,"Abdul-Wahab, Sabah A. Sick Building Syndrome: In Public Buildings and Workplaces. Berlin: Springer, 2011. Internet resource."
"Case Studies",4,"Pluschke, P. ''Indoor Air Pollution''. The Handbook of Environmental Chemistry, Volume 4F, 2004. Internet resource"
"Case study basics",1,"full citation"
"Case study basics",3,"Abdul-Wahab, Sabah A. Sick Building Syndrome: In Public Buildings and Workplaces. Berlin: Springer, 2011. Internet resource."
"Case study basics",4,"Pluschke, P. ''Indoor Air Pollution''. The Handbook of Environmental Chemistry, Volume 4F, 2004. Internet resource"
"Control Measures",1,"[http://water.epa.gov/infrastructure/drinkingwater/pws/index.cfm EPA Public Water Systems]"
"Control Measures",2,"Sobsey MD, Stauber C, Casanova L, Brown J and Elliott M (2008) Point of use household drinking water filtration: A practical, effective solution for providing sustained access to safe drinking water in the developing world. Environmental Science & Technology. 42 (12), 4261â4267."
"Control Measures",3,"[http://www.epa.gov/npdes/pubs/primer.pdf EPA Wastewater Treatment]"
"Control Measures",4," [http://www.cleanwaterservices.org/Content/Documents/About%20Us/Chlorine%20Disinfection%20Fact%20Sheet.pdf EPA Chlorine Fact Sheet]"
"Control Measures",5," [http://www.cleanwaterservices.org/Content/Documents/About%20Us/Chlorine%20Disinfection%20Fact%20Sheet.pdf EPA Chlorine Fact Sheet]"
"Control Measures",6,"[http://www.cleanwaterservices.org/Content/Documents/About%20Us/UV%20Disinfection%20Fact%20Sheet.pdf EPA UV Fact Sheet]"
"Control Measures",7,"[http://water.epa.gov/scitech/wastetech/upload/2002_06_28_mtb_ozon.pdf EPA Ozone Fact Sheet]"
"Control Measures",8,"[http://pdfs.journals.lww.com/pidj/2000/10001/Transmission_of_viral_respiratory_infections_in.2.pdf?token=method|ExpireAbsolute;source|Journals;ttl|1357583587236;payload|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;hash|rFOIEuYcyysDsrXtp3wpPg==] DA Goldman (2000)Transmission of viral respiratory infections in the homeâ¯: The Pediatric Infectious Disease Journal.Volume 19 - Issue 10 - pp S97-S102]"
"Control Measures",9,"[http://aem.asm.org/content/73/6/1687.full.pdf]Boone, Stephanie A., and Charles P. Gerba. 2007. âSignificance of Fomites in the Spread of Respiratory and Enteric Viral Disease.â Applied and Environmental Microbiology 73 (6) (March 15): 1687â1696. doi:10.1128/AEM.02051-06."
"Control Measures",10,"[http://isse.utk.edu/ccp/pubs/pdfs/HouseholdCleaners-wofigsandapps.pdf Household Cleaners Study]"
"Control Measures",11,"[http://www.unc.edu/depts/spice/dis/ICHE-2000-Jan-p33.pdf W. A. Rutala, S. L. Barbee, N. C. Aguiar, M. D. Sobsey, D. J. Weber
Infect Control Hosp Epidemiol. 2000 January; 21(1): 33â38. doi: 10.1086/501694]"
"Control Measures",12,"[http://online.liebertpub.com/doi/pdf/10.1089/bsp.2005.3.119 Remediation of Bacillus anthracis Contamination in the U.S. Department of Justice Mail Facility
]"
"Control Measures",13,"[http://www.epa.gov/iaq/voc.html EPA IAQ]"
"Control Measures",14," [http://www.epa.gov/iaq/biologic.html USEPA Indoor Air Quality Biologial]"
"Control Measures",15," [http://www.epa.gov/iaq/biologic.html USEPA Indoor Air Quality Biologial]"
"Control Measures",16," [http://www.fda.gov/Food/FoodSafety/HazardAnalysisCriticalControlPointsHACCP/default.htm FDA HACCP]"
"Control Measures",17," [http://www.fda.gov/Food/FoodSafety/RetailFoodProtection/FoodCode/default.htm FDA Food Code]"
"Control Measures",18," [http://www.fda.gov/downloads/Food/FoodSafety/RetailFoodProtection/FoodCode/FoodCode2009/UCM189448.pdf Food Code 2009]"
"Control Measures",19," [ftp://ftp.fao.org/codex/Publications/Booklets/Hygiene/FoodHygiene_2003e.pdf Codex Alimentarious]"
"Control Measures",20," [http://www.codexalimentarius.org/standards/list-of-standards/en/?no_cache=1 FAO Codex Standards]"
"Coxiella burnetii",1,"Parker, N. R., Barralet, J. H., & Bell, A. M. (25 February). Q fever. The Lancet, 367(9511), 679â688. doi:10.1016/S0140-6736(06)68266-4 [Http//:www.sciencedirect.com/science/article/pii/S0140673606682664 Full Text]"
"Coxiella burnetii",2,"[http://www.cdc.gov/qfever CDC Page]"
"Coxiella burnetii",3,"McQUISTON, J. H., Holman, R. C., McCALL, C. L., Childs, J. E., Swerdlow, D. L., & Thompson, H. A. (2006). National Surveillance and the Epidemiology of Human Q Fever in the United States, 1978â2004. The American Journal of Tropical Medicine and Hygiene, 75(1), 36â40. [http://www.ajtmh.org/content/75/1/36.full Full Text]"
"Coxiella burnetii",5,"Struble, K. Cunha, B. (2012) ""Q Fever"" Medscape Reference. http://emedicine.medscape.com/article/227156-overview#a0156"
"Coxiella burnetii",9,"Hartzell, J. D., Wood-Morris, R. N., Martinez, L. J., & Trotta, R. F. (2008). Q Fever: Epidemiology, Diagnosis, and Treatment. Mayo Clinic Proceedings, 83(5), 574â579. doi:10.4065/83.5.574 [http://download.journals.elsevierhealth.com/pdfs/journals/0025-6196/PIIS0025619611607337.pdf Full Text]"
"Coxiella burnetii: Dose Response Models",1,"Tamrakar SB, Haluska A, Haas CN and  Bartrand BA (2011) Dose-Response Model of Coxiella burnetii (Q Fever). Risk Analysis. 31(1), 120-128."
"Coxiella burnetii: Dose Response Models",2,"Williams JC and Cantrell JL (1982) Biological and immunological properties of Coxiella burnetii vaccines in C57BL/1OScN endotoxin-nonresponder mice. Infection and Immunity 35(3), 1091â1102."
"Coxiella burnetii: Dose Response Models",3,"Scott G, Williams JC, Stephenson EH (1987) Animal models in Q fever: pathological responses of inbred mice to phase I Coxiella Burnetii. Journal of General Microbiology. 133(3), 691â700."
"Cryptosporidium parvum",1,"CDC (2011) âParasites â Cryptosporidium (also known as âCryptoâ): Epidemiology & Risk Factorsâ Centers for Disease Control and Prevention.  Retrieved on 1-23-12 from http://www.cdc.gov/parasites/crypto/epi.html#one "
"Cryptosporidium parvum",2,"Ungar, B. L., Burris, J. A., Quinn, C. A., & Finkelman, F. D. (1990). New mouse models for chronic Cryptosporidium infection in immunodeficient hosts. Infection and Immunity, 58(4), 961â969."
"Cryptosporidium parvum",3,"Mach O, Lu L , Creek T, Bowen A, Arvelo W, Smit M, Masunge J, Brennan M, and Handzel T. (2009) Population-Based Study of a Widespread Outbreak of Diarrhea Associated with Increased Mortality and Malnutrition in Botswana, JanuaryâMarch, 2006. Am. J. Trop. Med. Hyg., 80(5): 812â818 [http://www.ajtmh.org.proxy1.cl.msu.edu/content/80/5/812.full.pdf+html Full Text]"
"Cryptosporidium parvum",4,"Connolly, G. M., Dryden, M. S., Shanson, D. C., & Gazzard, B. G. (1988). Cryptosporidial diarrhoea in AIDS and its treatment. Gut, 29(5), 593â597.
"
"Cryptosporidium parvum",5,"Ungar, B. L. P., Soave, R., Fayer, R., & Nash, T. E. (1986). Enzyme Immunoassay Detection of Immunoglobulin M and G Antibodies to Cryptosporidium in Immunocompetent and Immunocompromised Persons. Journal of Infectious Diseases, 153(3), 570â578. doi:10.1093/infdis/153.3.570
"
"Cryptosporidium parvum",7,"Cabada, M. Burke, C. (2011) âCryptosporidiosisâ  Medscape Reference: Drugs, Diseases & Procedures: Cryptosporidiosis.  Retrieved on 1-23-12 from http://emedicine.medscape.com/article/215490-overview#a0156"
"Cryptosporidium parvum",8," Yoder, JS, Harral, C., and Beach MJ. (2010) âCryptosporidiosis Surveillance â United States, 2006â2008. MMWR.â Centers for Disease Control and Prevention.  59 (No. SS-6): 1-14.  Retrieved on 1-23-12 from http://www.cdc.gov/mmwr/pdf/ss/ss5906.pdf "
"Cryptosporidium parvum",9,"Neil J. Hoxie, et al. (December 1997), ""Cryptosporidiosis-Associated Mortality Following a Massive Waterbome Outbreak in Milwaukee, Wisconsin"", American Journal of Public Health 87 (12): 2032â2035. Retrieved on 1-23-12 from http://ajph.aphapublications.org/doi/pdf/10.2105/AJPH.87.12.2032"
"Cryptosporidium parvum",10,http://en.wikipedia.org/wiki/Cryptosporidium
"Dose Response Modeling R Code",1," Haas, C.N., Rose, J.B. and Gerba, C.P. 2014. Quantitative Microbial Risk Assessment. Second. J. Wiley and Sons. [http://www.wiley.com/WileyCDA/WileyTitle/productCd-1118145291,subjectCd-CH20.html/ Wiley Link] "
"Dose Response Modeling R Code",2," Weir, M.H. 2016. âDose-Response Modeling and Use: Challenges and Uncertainties in Environmental Exposure.â In Manual of Environmental Microbiology, 4th ed., 3.5.3â1 â 3.5.3â17. ASM Press. [http://www.asmscience.org/content/book/10.1128/9781555818821 Link to ASM book page] "
"Dose Response Modeling R Code",3,"Weir, M.H., Mitchell, J., Flynn, W.B., Pope, J.M. 2016(in press). Development of a Microbial Dose Response Visualization and Modelling Application for QMRA Modelers and Educators. Environmental Modelling and Software "
"Dosing Experiments",1,"Lathem WW, Crosby SD, Miller VL and Goldman WE (2005) Progression of primary pneumonic plague: A mouse model of infection, pathology, and bacterial transcriptional activity. Proceedings of the National Academy of Sciences of the United States of America. 102 (49), 17786â17791."
"Dosing Experiments",2,"Parent MA, Berggren KN, Kummer LW, Wilhelm LB, Szaba FM, Mullarky IK and Smiley ST (2005) Cell-Mediated Protection against Pulmonary Yersinia pestis Infection. Infection and Immunity. 73 (11), 7304â7310."
"Dosing Experiments",3,"Rogers JV, Choi YW, Giannunzio LF, Sabourin PJ, Bornman DM, Blosser EG and Sabourin CLK (2007) Transcriptional responses in spleens from mice exposed to Yersinia pestis CO92. Microbial Pathogenesis. 43 (2â3), 67â77."
"Dosing Experiments",4,"Chen TH, Foster LE and Meyer KF (1974) Comparison of the Immune Response to Three Different Yersinia pestis Vaccines in Guinea Pigs and Langurs. Journal of Infectious Diseases. 129 (Supplement 1), S53âS61."
"Dosing Experiments",5,"Chen TH, Foster LE and Meyer KF (1974) Comparison of the Immune Response to Three Different Yersinia pestis Vaccines in Guinea Pigs and Langurs. Journal of Infectious Diseases. 129 (Supplement 1), S53âS61."
"Dosing Experiments",6,"Chen TH, Foster LE and Meyer KF (1974) Comparison of the Immune Response to Three Different Yersinia pestis Vaccines in Guinea Pigs and Langurs. Journal of Infectious Diseases. 129 (Supplement 1), S53âS61."
"Dosing Experiments",7,"SPECK RS and WOLOCHOW H (1957) Studies on the experimental epidemiology of respiratory infections. VIII. Experimental pneumonic plague in Macacus rhesus. The Journal of infectious diseases. 100 (1), 58â69."
"Dosing Experiments",8,"HOLDENRIED R and QUAN SF (1956) Susceptibility of New Mexico rodents to experimental plague. Public health reports. 71 (10), 979â984."
"Dosing Experiments",9,"Marshall RG and Gerone PJ (1961) SUSCEPTIBILITY OF SUCKLING MICE TO VARIOLA VIRUS. Journal of Bacteriology. 82 (1), 15â19."
"Dosing Experiments",10,"Marshall RG and Gerone PJ (1961) SUSCEPTIBILITY OF SUCKLING MICE TO VARIOLA VIRUS. Journal of Bacteriology. 82 (1), 15â19."
"Dosing Experiments",11,"Marshall RG and Gerone PJ (1961) SUSCEPTIBILITY OF SUCKLING MICE TO VARIOLA VIRUS. Journal of Bacteriology. 82 (1), 15â19."
"Dosing Experiments",12,"Marshall RG and Gerone PJ (1961) SUSCEPTIBILITY OF SUCKLING MICE TO VARIOLA VIRUS. Journal of Bacteriology. 82 (1), 15â19."
"Dosing Experiments",13,"Jahrling PB, Smith S, Hesse RA and Rhoderick JB (1982) Pathogenesis of Lassa virus infection in guinea pigs. Infection and Immunity. 37 (2), 771â778."
"Dosing Experiments",14,"Jahrling PB, Smith S, Hesse RA and Rhoderick JB (1982) Pathogenesis of Lassa virus infection in guinea pigs. Infection and Immunity. 37 (2), 771â778."
"Dosing Experiments",15,"Stephenson EH, Larson EW and Dominik JW (1984) Effect of environmental factors on aerosol-induced Lassa virus infection. Journal of medical virology. 14 (4), 295â303."
"Dosing Experiments",16,"Stephenson EH, Larson EW and Dominik JW (1984) Effect of environmental factors on aerosol-induced Lassa virus infection. Journal of medical virology. 14 (4), 295â303."
"Dosing Experiments",17,"Liu B, Koo GC, Yap EH, Chua KL and Gan Y-H (2002) Model of Differential Susceptibility to Mucosal Burkholderia pseudomallei Infection. Infection and Immunity. 70 (2), 504â511."
"Dosing Experiments",18,"Liu B, Koo GC, Yap EH, Chua KL and Gan Y-H (2002) Model of Differential Susceptibility to Mucosal Burkholderia pseudomallei Infection. Infection and Immunity. 70 (2), 504â511."
"Dosing Experiments",19,"Schell MA, Ulrich RL, Ribot WJ, Brueggemann EE, Hines HB, Chen D, Lipscomb L, Kim HS, MrÃ¡zek J, Nierman WC and DeShazer D (2007) Type VI secretion is a major virulence determinant in Burkholderia mallei. Molecular Microbiology. 64 (6), 1466â1485."
"Dosing Experiments",20,"Schell MA, Ulrich RL, Ribot WJ, Brueggemann EE, Hines HB, Chen D, Lipscomb L, Kim HS, MrÃ¡zek J, Nierman WC and DeShazer D (2007) Type VI secretion is a major virulence determinant in Burkholderia mallei. Molecular Microbiology. 64 (6), 1466â1485."
"Dosing Experiments",21,"Miller WR, Pannell L, Cravitz L, Tanner WA and Rosebury T (1948) Studies on Certain Biological Characteristics of Malleomyces mallei and Malleomyces pseudomallei. Journal of Bacteriology. 55 (1), 127â135."
"Dosing Experiments",22,"Miller WR, Pannell L, Cravitz L, Tanner WA and Rosebury T (1948) Studies on Certain Biological Characteristics of Malleomyces mallei and Malleomyces pseudomallei. Journal of Bacteriology. 55 (1), 127â135."
"Dosing Experiments",23,"Brett PJ and Woods DE (2000) Pathogenesis of and immunity to melioidosis. Acta Tropica. 74 (2â3), 201â210."
"Dosing Experiments",24,"Russell-Lodrigue KE, Zhang GQ, McMurray DN and Samuel JE (2006) Clinical and Pathologic Changes in a Guinea Pig Aerosol Challenge Model of Acute Q Fever. Infection and Immunity. 74 (11), 6085â6091."
"Dosing Experiments",25,"Andoh M, Naganawa T, Hotta A, Yamaguchi T, Fukushi H, Masegi T and Hirai K (2003) SCID Mouse Model for Lethal Q Fever. Infection and Immunity. 71 (8), 4717â4723."
"Dosing Experiments",26,"Scott GH, Williams JC and Stephenson EH (1987) Animal Models in Q Fever: Pathological Responses of Inbred Mice to Phase I Coxiella burnetii. Journal of General Microbiology. 133 (3), 691â700."
"Dosing Experiments",27,"Scott GH, Williams JC and Stephenson EH (1987) Animal Models in Q Fever: Pathological Responses of Inbred Mice to Phase I Coxiella burnetii. Journal of General Microbiology. 133 (3), 691â700."
"Dosing Experiments",28,"Williams JC and Cantrell JL (1982) Biological and immunological properties of Coxiella burnetii vaccines in C57BL/10ScN endotoxin-nonresponder mice. Infection and Immunity. 35 (3), 1091â1102."
"Dosing Experiments",29,"BENENSON AS and TIGERTT WD (1956) Studies on Q fever in man. Transactions of the Association of American Physicians. 69, 98â104."
"Dosing Experiments",30,"Hamory BH, Couch RB, Douglas RG Jr, Black SH and Knight V (1972) Characterization of the infectious unit for man of two respiratory viruses. Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.). 139 (3), 890â893."
"Dosing Experiments",31,"Couch RB, Cate TR, Douglas RG, Gerone PJ and Knight V (1966) Effect of route of inoculation on experimental respiratory viral disease in volunteers and evidence for airborne transmission. Bacteriological Reviews. 30 (3), 517â529."
"Dosing Experiments",32,"Kurtz JB, Lee TW, Craig JW and Reed SE (1979) Astrovirus infection in volunteers. Journal of medical virology. 3 (3), 221â230."
"Dosing Experiments",33,"Hornick RB, Music SI, Wenzel R, Cash R, Libonati JP, Snyder MJ and Woodward TE (1971) The Broad Street pump revisited: response of volunteers to ingested cholera vibrios. Bulletin of the New York Academy of Medicine. 47 (10), 1181â1191."
"Dosing Experiments",34,"Hornick RB, Music SI, Wenzel R, Cash R, Libonati JP, Snyder MJ and Woodward TE (1971) The Broad Street pump revisited: response of volunteers to ingested cholera vibrios. Bulletin of the New York Academy of Medicine. 47 (10), 1181â1191."
"Dosing Experiments",35,"Hornick RB, Music SI, Wenzel R, Cash R, Libonati JP, Snyder MJ and Woodward TE (1971) The Broad Street pump revisited: response of volunteers to ingested cholera vibrios. Bulletin of the New York Academy of Medicine. 47 (10), 1181â1191."
"Dosing Experiments",36,"Black RE, Levine MM, Clements ML, Hughes TP and Blaser MJ (1988) Experimental Campylobacter jejuni Infection in Humans. Journal of Infectious Diseases. 157 (3), 472â479."
"Dosing Experiments",37,"Kotak BG, Kenefick SL, Fritz DL, Rousseaux CG, Prepas EE and Hrudey SE (1993) Occurrence and toxicological evaluation of cyanobacterial toxins in Alberta lakes and farm dugouts. Water Research. 27 (3), 495â506."
"Dosing Experiments",38,"DuPont HL, Formal SB, Hornick RB, Snyder MJ, Libonati JP, Sheahan DG, LaBrec EH and Kalas JP (1971) Pathogenesis of Escherichia coli diarrhea. The New England journal of medicine. 285 (1), 1â9."
"Dosing Experiments",39,"DuPont HL, Formal SB, Hornick RB, Snyder MJ, Libonati JP, Sheahan DG, LaBrec EH and Kalas JP (1971) Pathogenesis of Escherichia coli diarrhea. The New England journal of medicine. 285 (1), 1â9."
"Dosing Experiments",40,"DuPont HL, Formal SB, Hornick RB, Snyder MJ, Libonati JP, Sheahan DG, LaBrec EH and Kalas JP (1971) Pathogenesis of Escherichia coli diarrhea. The New England journal of medicine. 285 (1), 1â9."
"Dosing Experiments",41,"DuPont HL, Formal SB, Hornick RB, Snyder MJ, Libonati JP, Sheahan DG, LaBrec EH and Kalas JP (1971) Pathogenesis of Escherichia coli diarrhea. The New England journal of medicine. 285 (1), 1â9."
"Dosing Experiments",42,"JUNE RC, FERGUSON WW and WORFEL MT (1953) Experiments in feeding adult volunteers with Escherichia coli 55, B5, a coliform organism associated with infant diarrhea. American journal of hygiene. 57 (2), 222â236."
"Dosing Experiments",43,"Feeguson WW and June EC (1952) Experiments on Feeding Adult Volunteers with Escherichia Coli 111, B4, a Coliform Organism Associated with Infant Diarrhea. American Journal of Epidemiology. 55 (2), 155â160."
"Dosing Experiments",44,"Haas CN, Rose JB and Gerba CP (1999) Quantitative Microbial Risk Assessment. John Wiley and Sons"
"Dosing Experiments",45,"RENDTORFF RC (1954) The experimental transmission of human intestinal protozoan parasites. I. Endamoeba coli cysts given in capsules. American journal of hygiene. 59 (2), 196â208."
"Dosing Experiments",46,"RENDTORFF RC (1954) The experimental transmission of human intestinal protozoan parasites. II. Giardia lamblia cysts given in capsules. American journal of hygiene. 59 (2), 209â220."
"Dosing Experiments",47,"Erlandsen SL, Sherlock LA, Januschka M, Schupp DG, Schaefer FW, Jakubowski W and Bemrick WJ (1988) Cross-species transmission of Giardia spp.: inoculation of beavers and muskrats with cysts of human, beaver, mouse, and muskrat origin. Applied and Environmental Microbiology. 54 (11), 2777â2785."
"Dosing Experiments",48,"Erlandsen SL, Sherlock LA, Januschka M, Schupp DG, Schaefer FW, Jakubowski W and Bemrick WJ (1988) Cross-species transmission of Giardia spp.: inoculation of beavers and muskrats with cysts of human, beaver, mouse, and muskrat origin. Applied and Environmental Microbiology. 54 (11), 2777â2785."
"Dosing Experiments",49,"Istre GR, Dunlop TS, Gaspard GB and Hopkins RS (1984) Waterborne giardiasis at a mountain resort: evidence for acquired immunity. American Journal of Public Health. 74 (6), 602â604."
"Dosing Experiments",50,"Labatiuk CW, Schaefer FW, Finch GR and Belosevic M (1991) Comparison of animal infectivity, excystation, and fluorogenic dye as measures of Giardia muris cyst inactivation by ozone. Applied and Environmental Microbiology. 57 (11), 3187â3192."
"Dosing Experiments",51,"WARD R, KRUGMAN S, GILES JP, JACOBS AM and BODANSKY O (1958) Infectious hepatitis; studies of its natural history and prevention. The New England journal of medicine. 258 (9), 407â416."
"Dosing Experiments",52,"WARD R, KRUGMAN S, GILES JP, JACOBS AM and BODANSKY O (1958) Infectious hepatitis; studies of its natural history and prevention. The New England journal of medicine. 258 (9), 407â416."
"Dosing Experiments",53,"Taylor-Robinson D and Bynoe ML (1963) Para-influenza 2 virus infections in adult volunteers. The Journal of Hygiene. 61 (4), 407â417."
"Dosing Experiments",54,"Taylor-Robinson D and Bynoe ML (1963) Para-influenza 2 virus infections in adult volunteers. The Journal of Hygiene. 61 (4), 407â417."
"Dosing Experiments",55,"CRAIGHEAD JE, COOK MK and CHANOCK RM (1960) Infection of hamsters with para influenza 3 virus. Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.). 104, 301â304."
"Dosing Experiments",56,"Koprowski H (1956) Immunization against Poliomyelitis with Living Attenuated Virus. The American Journal of Tropical Medicine and Hygiene. 5 (3), 440â452."
"Dosing Experiments",57,"Minor TE, Allen CI, Tsiatis AA, Nelson DB and DâAlessio DJ (1981) Human infective dose determinations for oral poliovirus type 1 vaccine in infants. Journal of Clinical Microbiology. 13 (2), 388â389."
"Dosing Experiments",58,"Koprowski H (1956) Immunization against Poliomyelitis with Living Attenuated Virus. The American Journal of Tropical Medicine and Hygiene. 5 (3), 440â452."
"Dosing Experiments",59,"SABIN AB (1955) Behavior of chimpanzee avirulent poliomyelitis viruses in experimentally infected human volunteers. The American journal of the medical sciences. 230 (1), 1â8."
"Dosing Experiments",60,"Katz M and Plotkin SA (1967) Minimal infective dose of attenuated poliovirus for man. American Journal of Public Health and the Nations Health. 57 (10), 1837â1840."
"Dosing Experiments",61,"SABIN AB (1955) Behavior of chimpanzee avirulent poliomyelitis viruses in experimentally infected human volunteers. The American journal of the medical sciences. 230 (1), 1â8."
"Dosing Experiments",62,"        Cliver, D. O. (1981). Experimental infection by waterborne enteroviruses. Journal of Food Protection. 44,861-865."
"Dosing Experiments",63,"        Cliver, D. O. (1981). Experimental infection by waterborne enteroviruses. Journal of Food Protection. 44,861-865."
"Dosing Experiments",64,"Hendley JO, Edmondson WP and Gwaltney JM (1972) Relation between Naturally Acquired Immunity and Infectivity of Two Rhinoviruses in Volunteers. Journal of Infectious Diseases. 125 (3), 243â248."
"Dosing Experiments",65,"Hendley JO, Edmondson WP and Gwaltney JM (1972) Relation between Naturally Acquired Immunity and Infectivity of Two Rhinoviruses in Volunteers. Journal of Infectious Diseases. 125 (3), 243â248."
"Dosing Experiments",66,"Graham DY, Dufour GR and Estes MK (1987) Minimal infective dose of rotavirus. Archives of virology. 92 (3-4), 261â271."
"Dosing Experiments",67,"Gouvea VS, Alencar AA, Barth OM, Castro L de, Fialho AM, AraÃºjo HP, Majerowicz S and Pereira HG (1986) Diarrhoea in Mice Infected with a Human Rotavirus. Journal of General Virology. 67 (3), 577â581."
"Dosing Experiments",68,"Payment P and Morin E (1990) Minimal infective dose of the OSU strain of porcine rotavirus. Archives of virology. 112 (3-4), 277â282."
"Dosing Experiments",69,"Ward RL, Bernstein DI, Young EC, Sherwood JR, Knowlton DR and Schiff GM (1986) Human Rotavirus Studies in Volunteers: Determination of Infectious Dose and Serological Response to Infection. Journal of Infectious Diseases. 154 (5), 871â880."
"Dosing Experiments",70,"Ward RL, Bernstein DI, Young EC, Sherwood JR, Knowlton DR and Schiff GM (1986) Human Rotavirus Studies in Volunteers: Determination of Infectious Dose and Serological Response to Infection. Journal of Infectious Diseases. 154 (5), 871â880."
"Dosing Experiments",71,"Hall CB, Douglas RG, Schnabel KC and Geiman JM (1981) Infectivity of respiratory syncytial virus by various routes of inoculation. Infection and Immunity. 33 (3), 779â783."
"Dosing Experiments",72,"Hall CB, Douglas RG, Schnabel KC and Geiman JM (1981) Infectivity of respiratory syncytial virus by various routes of inoculation. Infection and Immunity. 33 (3), 779â783."
"Dosing Experiments",73,"Hall CB, Douglas RG, Schnabel KC and Geiman JM (1981) Infectivity of respiratory syncytial virus by various routes of inoculation. Infection and Immunity. 33 (3), 779â783."
"Dosing Experiments",74,"Parrott RH, Kim HW, Brandt CD and Chanock RM (1974) Respiratory syncytial virus in infants and children. Preventive medicine. 3 (4), 473â480."
"Dosing Experiments",75,"Wright PF, Belshe RB, Kim HW, Van Voris LP and Chanock RM (1982) Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children. Infection and Immunity. 37 (1), 397â400."
"Dosing Experiments",76,"Plotkin SA, Cornfeld D and Ingalls TH (1965) Studies of immunization with living rubella virus. Trials in children with a strain cultured from an aborted fetus. American journal of diseases of children (1960). 110 (4), 381â389."
"Dosing Experiments",77,"Feldman RE, Baine WB, Nitzkin JL, Saslaw MS and Pollard RA (1974) Epidemiology of Salmonella typhi Infection in a Migrant Labor Camp in Dade County, Florida. Journal of Infectious Diseases. 130 (4), 334â342."
"Dosing Experiments",78,"Hornick RB, Woodward TE, McCrumb FR, Snyder MJ, Dawkins AT, Bulkeley JT, De la Macorra F and Corozza FA (1966) Study of induced typhoid fever in man. I. Evaluation of vaccine effectiveness. Transactions of the Association of American Physicians. 79, 361â367."
"Dosing Experiments",79,"Hornick RB, Greisman SE, Woodward TE, DuPont HL, Dawkins AT and Snyder MJ (1970) Typhoid fever: pathogenesis and immunologic control. The New England journal of medicine. 283 (13), 686â691."
"Dosing Experiments",80,"Levine MM, DuPont HL, Formal SB, Hornick RB, Takeuchi A, Gangarosa EJ, Snyder MJ and Libonati JP (1973) Pathogenesis of Shigella dysenteriae 1 (Shiga) Dysentery. Journal of Infectious Diseases. 127 (3), 261â270."
"Dosing Experiments",81,"DuPont HL, Hornick RB, Dawkins AT, Snyder MJ and Formal SB (1969) The Response of Man to Virulent Shigella flexneri 2a. Journal of Infectious Diseases. 119 (3), 296â299."
"Dosing Experiments",82,"DuPont HL, Hornick RB, Snyder MJ, Libonati JP, Formal SB and Gangarosa EJ (1972) Immunity in Shigellosis. I. Response of Man to Attenuated Strains of Shigella. Journal of Infectious Diseases. 125 (1), 5â11."
"Dosing Experiments",83,"Altboum Z, Gozes Y, Barnea A, Pass A, White M and Kobiler D (2002) Postexposure Prophylaxis against Anthrax: Evaluation of Various Treatment Regimens in Intranasally Infected Guinea Pigs. Infection and Immunity. 70 (11), 6231â6241."
"Dosing Experiments",84,"Altboum Z, Gozes Y, Barnea A, Pass A, White M and Kobiler D (2002) Postexposure Prophylaxis against Anthrax: Evaluation of Various Treatment Regimens in Intranasally Infected Guinea Pigs. Infection and Immunity. 70 (11), 6231â6241."
"Dosing Experiments",85,"Druett HA, Henderson DW, Packman L and Peacock S (1953) Studies on respiratory infection. The Journal of Hygiene. 51 (3), 359â371."
"Dosing Experiments",86,"Druett HA, Henderson DW, Packman L and Peacock S (1953) Studies on respiratory infection. The Journal of Hygiene. 51 (3), 359â371."
"Dosing Experiments",87,"JUNE RC, FERGUSON WW and WORFEL MT (1953) Experiments in feeding adult volunteers with Escherichia coli 55, B5, a coliform organism associated with infant diarrhea. American journal of hygiene. 57 (2), 222â236."
"Dosing Experiments",88,"Feeguson WW and June EC (1952) Experiments on Feeding Adult Volunteers with Escherichia Coli 111, B4, a Coliform Organism Associated with Infant Diarrhea. American Journal of Epidemiology. 55 (2), 155â160."
"Dosing Experiments",89,"Morgan DR, Johnson PC, DuPont HL, Satterwhite TK and Wood LV (1985) Lack of correlation between known virulence properties of Aeromonas hydrophila and enteropathogenicity for humans. Infection and Immunity. 50 (1), 62â65."
"Dosing Experiments",90,"Morgan DR, Johnson PC, DuPont HL, Satterwhite TK and Wood LV (1985) Lack of correlation between known virulence properties of Aeromonas hydrophila and enteropathogenicity for humans. Infection and Immunity. 50 (1), 62â65."
"Dosing Experiments",91,"Morgan DR, Johnson PC, DuPont HL, Satterwhite TK and Wood LV (1985) Lack of correlation between known virulence properties of Aeromonas hydrophila and enteropathogenicity for humans. Infection and Immunity. 50 (1), 62â65."
"Dosing Experiments",92,"Morgan DR, Johnson PC, DuPont HL, Satterwhite TK and Wood LV (1985) Lack of correlation between known virulence properties of Aeromonas hydrophila and enteropathogenicity for humans. Infection and Immunity. 50 (1), 62â65."
"Dosing Experiments",93,"Morgan DR, Johnson PC, DuPont HL, Satterwhite TK and Wood LV (1985) Lack of correlation between known virulence properties of Aeromonas hydrophila and enteropathogenicity for humans. Infection and Immunity. 50 (1), 62â65."
"Dosing Experiments",94,"Morgan DR, Johnson PC, DuPont HL, Satterwhite TK and Wood LV (1985) Lack of correlation between known virulence properties of Aeromonas hydrophila and enteropathogenicity for humans. Infection and Immunity. 50 (1), 62â65."
"Dosing Experiments",95,"DuPont HL, Formal SB, Hornick RB, Snyder MJ, Libonati JP, Sheahan DG, LaBrec EH and Kalas JP (1971) Pathogenesis of Escherichia coli diarrhea. The New England journal of medicine. 285 (1), 1â9."
"Dosing Experiments",96,"DuPont HL, Formal SB, Hornick RB, Snyder MJ, Libonati JP, Sheahan DG, LaBrec EH and Kalas JP (1971) Pathogenesis of Escherichia coli diarrhea. The New England journal of medicine. 285 (1), 1â9."
"Dosing Experiments",97,"DuPont HL, Formal SB, Hornick RB, Snyder MJ, Libonati JP, Sheahan DG, LaBrec EH and Kalas JP (1971) Pathogenesis of Escherichia coli diarrhea. The New England journal of medicine. 285 (1), 1â9."
"Dosing Experiments",98,"DuPont HL, Formal SB, Hornick RB, Snyder MJ, Libonati JP, Sheahan DG, LaBrec EH and Kalas JP (1971) Pathogenesis of Escherichia coli diarrhea. The New England journal of medicine. 285 (1), 1â9."
"Dosing Experiments",99,"DuPont HL, Formal SB, Hornick RB, Snyder MJ, Libonati JP, Sheahan DG, LaBrec EH and Kalas JP (1971) Pathogenesis of Escherichia coli diarrhea. The New England journal of medicine. 285 (1), 1â9."
"Dosing Experiments",100,"DuPont HL, Formal SB, Hornick RB, Snyder MJ, Libonati JP, Sheahan DG, LaBrec EH and Kalas JP (1971) Pathogenesis of Escherichia coli diarrhea. The New England journal of medicine. 285 (1), 1â9."
"Dosing Experiments",101,"DuPont HL, Formal SB, Hornick RB, Snyder MJ, Libonati JP, Sheahan DG, LaBrec EH and Kalas JP (1971) Pathogenesis of Escherichia coli diarrhea. The New England journal of medicine. 285 (1), 1â9."
"Dosing Experiments",102,"Buck AC and Cooke EM (1969) The Fate Of Ingested Pseudomonas Aeruginosa In Normal Persons. Journal of Medical Microbiology. 2 (4), 521â525."
"Dosing Experiments",103,"McCullough NB and Elsele CW (1951) Experimental Human Salmonellosis: I. Pathogenicity of Strains of Salmonella meleagridis and Salmonella anatum Obtained from Spray-Dried Whole Egg. The Journal of Infectious Diseases. 88 (3), 278â289."
"Dosing Experiments",104,"McCullough NB and Elsele CW (1951) Experimental Human Salmonellosis: I. Pathogenicity of Strains of Salmonella meleagridis and Salmonella anatum Obtained from Spray-Dried Whole Egg. The Journal of Infectious Diseases. 88 (3), 278â289."
"Dosing Experiments",105,"Black RE, Levine MM, Clements ML, Hughes TP and Blaser MJ (1988) Experimental Campylobacter jejuni Infection in Humans. Journal of Infectious Diseases. 157 (3), 472â479."
"Dosing Experiments",106,"Black RE, Levine MM, Clements ML, Hughes TP and Blaser MJ (1988) Experimental Campylobacter jejuni Infection in Humans. Journal of Infectious Diseases. 157 (3), 472â479."
"Dosing Experiments",107,"DuPont HL, Chappell CL, Sterling CR, Okhuysen PC, Rose JB and Jakubowski W (1995) The infectivity of Cryptosporidium parvum in healthy volunteers. The New England journal of medicine. 332 (13), 855â859."
"Dosing Experiments",108,"DuPont HL, Chappell CL, Sterling CR, Okhuysen PC, Rose JB and Jakubowski W (1995) The infectivity of Cryptosporidium parvum in healthy volunteers. The New England journal of medicine. 332 (13), 855â859."
"Dosing Experiments",109,"LEPOW ML, WARREN RJ, INGRAM VG, DAUGHERTY SC and ROBBINS FC (1962) Sabin type I (LSc2ab) oral poliomyelitis vaccine. Effect of dose upon response of newborn infants. American journal of diseases of children (1960). 104, 67â71."
"Dosing Experiments",110,"Katz M and Plotkin SA (1967) Minimal infective dose of attenuated poliovirus for man. American Journal of Public Health and the Nations Health. 57 (10), 1837â1840."
"Dosing Experiments",111,"Schiff GM, StefanoviÄ GM, Young EC, Sander DS, Pennekamp JK and Ward RL (1984) Studies of echovirus-12 in volunteers: determination of minimal infectious dose and the effect of previous infection on infectious dose. The Journal of infectious diseases. 150 (6), 858â866."
"Dosing Experiments",112,"Suptel, E.A. (1963) Pathogenesis of experimental Coxsackie virus infection. Archive of Virology. 7, 61-66"
"Dosing Experiments",113,"Couch RB, Cate TR, Gerone PJ, Fleet WF, Lang DJ, Griffith WR and Knight V (1965) Production of Illness with a Small-Particle Aerosol of Coxsackie A21*. Journal of Clinical Investigation. 44 (4), 535â542."
"Dosing Experiments",114,"Couch RB, Cate TR, Gerone PJ, Fleet WF, Lang DJ, Griffith WR and Knight V (1965) Production of Illness with a Small-Particle Aerosol of Coxsackie A21*. Journal of Clinical Investigation. 44 (4), 535â542."
"Dosing Experiments",115,"Couch RB, Cate TR, Gerone PJ, Fleet WF, Lang DJ, Griffith WR and Knight V (1965) Production of Illness with a Small-Particle Aerosol of Coxsackie A21*. Journal of Clinical Investigation. 44 (4), 535â542."
"Dosing Experiments",116,"Couch RB, Cate TR, Gerone PJ, Fleet WF, Lang DJ, Griffith WR and Knight V (1965) Production of Illness with a Small-Particle Aerosol of Coxsackie A21*. Journal of Clinical Investigation. 44 (4), 535â542."
"Dosing Experiments",117,"Couch RB, Knight V, Gerone PJ, Cate TR and Douglas RG (1969) Factors influencing response of volunteers to inoculation with Coxsackie virus A type 21. The American review of respiratory disease. 99 (1), 24â30."
"Dosing Experiments",118,"Spickard A, Evans H, Knight V and Johnson K (1963) ACUTE RESPIRATORY DISEASE IN NORMAL VOLUNTEERS ASSOCIATED WITH COXSACKIE A-21 VIRAL INFECTION. III. RESPONSE TO NASOPHARYNGEAL AND ENTERIC INOCULATION. Journal of Clinical Investigation. 42 (6), 840â852."
"Dosing Experiments",119,"Spickard A, Evans H, Knight V and Johnson K (1963) ACUTE RESPIRATORY DISEASE IN NORMAL VOLUNTEERS ASSOCIATED WITH COXSACKIE A-21 VIRAL INFECTION. III. RESPONSE TO NASOPHARYNGEAL AND ENTERIC INOCULATION. Journal of Clinical Investigation. 42 (6), 840â852."
"Dosing Experiments",120,"Spickard A, Evans H, Knight V and Johnson K (1963) ACUTE RESPIRATORY DISEASE IN NORMAL VOLUNTEERS ASSOCIATED WITH COXSACKIE A-21 VIRAL INFECTION. III. RESPONSE TO NASOPHARYNGEAL AND ENTERIC INOCULATION. Journal of Clinical Investigation. 42 (6), 840â852."
"Dosing Experiments",121,"Spickard A, Evans H, Knight V and Johnson K (1963) ACUTE RESPIRATORY DISEASE IN NORMAL VOLUNTEERS ASSOCIATED WITH COXSACKIE A-21 VIRAL INFECTION. III. RESPONSE TO NASOPHARYNGEAL AND ENTERIC INOCULATION. Journal of Clinical Investigation. 42 (6), 840â852."
"Dosing Experiments",122,"Spickard A, Evans H, Knight V and Johnson K (1963) ACUTE RESPIRATORY DISEASE IN NORMAL VOLUNTEERS ASSOCIATED WITH COXSACKIE A-21 VIRAL INFECTION. III. RESPONSE TO NASOPHARYNGEAL AND ENTERIC INOCULATION. Journal of Clinical Investigation. 42 (6), 840â852."
"Dosing Experiments",123,"Spickard A, Evans H, Knight V and Johnson K (1963) ACUTE RESPIRATORY DISEASE IN NORMAL VOLUNTEERS ASSOCIATED WITH COXSACKIE A-21 VIRAL INFECTION. III. RESPONSE TO NASOPHARYNGEAL AND ENTERIC INOCULATION. Journal of Clinical Investigation. 42 (6), 840â852."
"Dosing Experiments",124,"Ward RL, Bernstein DI, Young EC, Sherwood JR, Knowlton DR and Schiff GM (1986) Human Rotavirus Studies in Volunteers: Determination of Infectious Dose and Serological Response to Infection. Journal of Infectious Diseases. 154 (5), 871â880."
"Dosing Experiments",125,"Kotak BG, Kenefick SL, Fritz DL, Rousseaux CG, Prepas EE and Hrudey SE (1993) Occurrence and toxicological evaluation of cyanobacterial toxins in Alberta lakes and farm dugouts. Water Research. 27 (3), 495â506."
"Dosing Experiments",126,"Kotak BG, Kenefick SL, Fritz DL, Rousseaux CG, Prepas EE and Hrudey SE (1993) Occurrence and toxicological evaluation of cyanobacterial toxins in Alberta lakes and farm dugouts. Water Research. 27 (3), 495â506."
"Dosing Experiments",127,"Kotak BG, Kenefick SL, Fritz DL, Rousseaux CG, Prepas EE and Hrudey SE (1993) Occurrence and toxicological evaluation of cyanobacterial toxins in Alberta lakes and farm dugouts. Water Research. 27 (3), 495â506."
"Dosing Experiments",128,"McCullough NB and Elsele CW (1951) Experimental Human Salmonellosis: I. Pathogenicity of Strains of Salmonella meleagridis and Salmonella anatum Obtained from Spray-Dried Whole Egg. The Journal of Infectious Diseases. 88 (3), 278â289."
"Dosing Experiments",129,"McCullough NB and Elsele CW (1951) Experimental Human Salmonellosis: I. Pathogenicity of Strains of Salmonella meleagridis and Salmonella anatum Obtained from Spray-Dried Whole Egg. The Journal of Infectious Diseases. 88 (3), 278â289."
"Dosing Experiments",130,"McCullough NB and Elsele CW (1951) Experimental Human Salmonellosis: I. Pathogenicity of Strains of Salmonella meleagridis and Salmonella anatum Obtained from Spray-Dried Whole Egg. The Journal of Infectious Diseases. 88 (3), 278â289."
"Dosing Experiments",131,"McCullough NB and Elsele CW (1951) Experimental Human Salmonellosis: I. Pathogenicity of Strains of Salmonella meleagridis and Salmonella anatum Obtained from Spray-Dried Whole Egg. The Journal of Infectious Diseases. 88 (3), 278â289."
"Dosing Experiments",132,"McCullough NB and Elsele CW (1951) Experimental Human Salmonellosis: I. Pathogenicity of Strains of Salmonella meleagridis and Salmonella anatum Obtained from Spray-Dried Whole Egg. The Journal of Infectious Diseases. 88 (3), 278â289."
"Dosing Experiments",133,"McCullough NB and Elsele CW (1951) Experimental Human Salmonellosis: I. Pathogenicity of Strains of Salmonella meleagridis and Salmonella anatum Obtained from Spray-Dried Whole Egg. The Journal of Infectious Diseases. 88 (3), 278â289."
"Dosing Experiments",134,"McCullough NB and Elsele CW (1951) Experimental Human Salmonellosis: I. Pathogenicity of Strains of Salmonella meleagridis and Salmonella anatum Obtained from Spray-Dried Whole Egg. The Journal of Infectious Diseases. 88 (3), 278â289."
"Dosing Experiments",135,"McCullough NB and Elsele CW (1951) Experimental Human Salmonellosis: I. Pathogenicity of Strains of Salmonella meleagridis and Salmonella anatum Obtained from Spray-Dried Whole Egg. The Journal of Infectious Diseases. 88 (3), 278â289."
"Dosing Experiments",136,"Black RE, Levine MM, Clements ML, Hughes TP and Blaser MJ (1988) Experimental Campylobacter jejuni Infection in Humans. Journal of Infectious Diseases. 157 (3), 472â479."
"Dosing Experiments",137,"Black RE, Levine MM, Clements ML, Hughes TP and Blaser MJ (1988) Experimental Campylobacter jejuni Infection in Humans. Journal of Infectious Diseases. 157 (3), 472â479."
"Dosing Experiments",138,"Messner MJ, Chappell CL and Okhuysen PC (2001) Risk Assessment for Cryptosporidium: A Hierarchical Bayesian Analysis of Human Dose Response Data. Water Research. 35 (16), 3934â3940."
"Dosing Experiments",139,"Messner MJ, Chappell CL and Okhuysen PC (2001) Risk Assessment for Cryptosporidium: A Hierarchical Bayesian Analysis of Human Dose Response Data. Water Research. 35 (16), 3934â3940."
"Dosing Experiments",140,"Messner MJ, Chappell CL and Okhuysen PC (2001) Risk Assessment for Cryptosporidium: A Hierarchical Bayesian Analysis of Human Dose Response Data. Water Research. 35 (16), 3934â3940."
"Dosing Experiments",141,"Coster TS, Wolf MK, Hall ER, Cassels FJ, Taylor DN, Liu CT, Trespalacios FC, DeLorimier A, Angleberger DR and McQueen CE (2007) Immune response, ciprofloxacin activity, and gender differences after human experimental challenge by two strains of enterotoxigenic Escherichia coli. Infection and immunity. 75 (1), 252â259."
"Dosing Experiments",142,"Levine MM, Nalin DR, Hoover DL, Bergquist EJ, Hornick RB and Young CR (1979) Immunity to Enterotoxigenic Escherichia coli. Infection and Immunity. 23 (3), 729â736."
"Dosing Experiments",143,"Levine MM, Nalin DR, Hoover DL, Bergquist EJ, Hornick RB and Young CR (1979) Immunity to Enterotoxigenic Escherichia coli. Infection and Immunity. 23 (3), 729â736."
"Dosing Experiments",144,"Levine MM, Nalin DR, Hoover DL, Bergquist EJ, Hornick RB and Young CR (1979) Immunity to Enterotoxigenic Escherichia coli. Infection and Immunity. 23 (3), 729â736."
"Dosing Experiments",145,"Levine MM, Nalin DR, Hoover DL, Bergquist EJ, Hornick RB and Young CR (1979) Immunity to Enterotoxigenic Escherichia coli. Infection and Immunity. 23 (3), 729â736."
"Dosing Experiments",146,"Levine MM, Nalin DR, Hoover DL, Bergquist EJ, Hornick RB and Young CR (1979) Immunity to Enterotoxigenic Escherichia coli. Infection and Immunity. 23 (3), 729â736."
"Dosing Experiments",147,"Levine MM, Nalin DR, Hoover DL, Bergquist EJ, Hornick RB and Young CR (1979) Immunity to Enterotoxigenic Escherichia coli. Infection and Immunity. 23 (3), 729â736."
"Dosing Experiments",148,"Levine MM, Nalin DR, Hoover DL, Bergquist EJ, Hornick RB and Young CR (1979) Immunity to Enterotoxigenic Escherichia coli. Infection and Immunity. 23 (3), 729â736."
"Dosing Experiments",149,"Levine MM, Nalin DR, Hoover DL, Bergquist EJ, Hornick RB and Young CR (1979) Immunity to Enterotoxigenic Escherichia coli. Infection and Immunity. 23 (3), 729â736."
"Dosing Experiments",150,"Tacket CO, Sztein MB, Losonsky G, Abe A, Finlay BB, McNamara BP, Fantry GT, James SP, Nataro JP, Levine MM and Donnenberg MS (2000) Role of EspB in Experimental Human Enteropathogenic Escherichia coli Infection. Infection and Immunity. 68 (6), 3689â3695."
"Dosing Experiments",151,"Tacket CO, Sztein MB, Losonsky G, Abe A, Finlay BB, McNamara BP, Fantry GT, James SP, Nataro JP, Levine MM and Donnenberg MS (2000) Role of EspB in Experimental Human Enteropathogenic Escherichia coli Infection. Infection and Immunity. 68 (6), 3689â3695."
"Dosing Experiments",152,"Donnenberg MS, Tacket CO, James SP, Losonsky G, Nataro JP, Wasserman SS, Kaper JB and Levine MM (1993) Role of the eaeA gene in experimental enteropathogenic Escherichia coli infection. Journal of Clinical Investigation. 92 (3), 1412â1417."
"Dosing Experiments",153,"Donnenberg MS, Tacket CO, James SP, Losonsky G, Nataro JP, Wasserman SS, Kaper JB and Levine MM (1993) Role of the eaeA gene in experimental enteropathogenic Escherichia coli infection. Journal of Clinical Investigation. 92 (3), 1412â1417."
"Dosing Experiments",154,"Donnenberg MS, Tacket CO, James SP, Losonsky G, Nataro JP, Wasserman SS, Kaper JB and Levine MM (1993) Role of the eaeA gene in experimental enteropathogenic Escherichia coli infection. Journal of Clinical Investigation. 92 (3), 1412â1417."
"Dosing Experiments",155,"Donnenberg MS, Tacket CO, James SP, Losonsky G, Nataro JP, Wasserman SS, Kaper JB and Levine MM (1993) Role of the eaeA gene in experimental enteropathogenic Escherichia coli infection. Journal of Clinical Investigation. 92 (3), 1412â1417."
"Dosing Experiments",156,"Donnenberg MS, Tacket CO, James SP, Losonsky G, Nataro JP, Wasserman SS, Kaper JB and Levine MM (1993) Role of the eaeA gene in experimental enteropathogenic Escherichia coli infection. Journal of Clinical Investigation. 92 (3), 1412â1417."
"Dosing Experiments",157,"Donnenberg MS, Tacket CO, James SP, Losonsky G, Nataro JP, Wasserman SS, Kaper JB and Levine MM (1993) Role of the eaeA gene in experimental enteropathogenic Escherichia coli infection. Journal of Clinical Investigation. 92 (3), 1412â1417."
"Dosing Experiments",158,"Clements ML, Levine MM, Black RE, Robins-Browne RM, Cisneros LA, Drusano GL, Lanata CF and Saah AJ (1981) Lactobacillus prophylaxis for diarrhea due to enterotoxigenic Escherichia coli. Antimicrobial Agents and Chemotherapy. 20 (1), 104â108."
"Dosing Experiments",159,"Clements ML, Levine MM, Black RE, Robins-Browne RM, Cisneros LA, Drusano GL, Lanata CF and Saah AJ (1981) Lactobacillus prophylaxis for diarrhea due to enterotoxigenic Escherichia coli. Antimicrobial Agents and Chemotherapy. 20 (1), 104â108."
"Dosing Experiments",160,"Levine MM, Caplan ES, Waterman D, Cash RA, Hornick RB and Snyder MJ (1977) Diarrhea caused by Escherichia coli that produce only heat-stable enterotoxin. Infection and Immunity. 17 (1), 78â82."
"Dosing Experiments",161,"Levine MM, Caplan ES, Waterman D, Cash RA, Hornick RB and Snyder MJ (1977) Diarrhea caused by Escherichia coli that produce only heat-stable enterotoxin. Infection and Immunity. 17 (1), 78â82."
"Dosing Experiments",162,"Cash RA, Music SI, Libonati JP, Snyder MJ, Wenzel RP and Hornick RB (1974) Response of Man to Infection with Vibrio cholerae. I. Clinical, Serologic, and Bacteriologic Responses to a Known Inoculum. The Journal of Infectious Diseases. 129 (1), 45â52."
"Dosing Experiments",163,"Levine MM, Rennels MB, Cisneros L, Hughes TP, Nalin DR and Young CR (1980) Lack of Person-to-Person Transmission of Enterotoxigenic Escherichia Coli Despite Close Contact. American Journal of Epidemiology. 111 (3), 347â355."
"Dosing Experiments",164,"Teunis PFM, Moe CL, Liu P, E. Miller S, Lindesmith L, Baric RS, Le Pendu J and Calderon RL (2008) Norwalk virus: How infectious is it? Journal of Medical Virology. 80 (8), 1468â1476."
"Dosing Experiments",165,"Teunis PFM, Moe CL, Liu P, E. Miller S, Lindesmith L, Baric RS, Le Pendu J and Calderon RL (2008) Norwalk virus: How infectious is it? Journal of Medical Virology. 80 (8), 1468â1476."
"Dosing Experiments",166,"Teunis PFM, Moe CL, Liu P, E. Miller S, Lindesmith L, Baric RS, Le Pendu J and Calderon RL (2008) Norwalk virus: How infectious is it? Journal of Medical Virology. 80 (8), 1468â1476."
"Dosing Experiments",167,"Teunis PFM, Moe CL, Liu P, E. Miller S, Lindesmith L, Baric RS, Le Pendu J and Calderon RL (2008) Norwalk virus: How infectious is it? Journal of Medical Virology. 80 (8), 1468â1476."
"Dosing Experiments",168,"Pai CH, Kelly JK and Meyers GL (1986) Experimental infection of infant rabbits with verotoxin-producing Escherichia coli. Infection and Immunity. 51 (1), 16â23."
"Dosing Experiments",169,"Pai CH, Kelly JK and Meyers GL (1986) Experimental infection of infant rabbits with verotoxin-producing Escherichia coli. Infection and Immunity. 51 (1), 16â23."
"Dosing Experiments",170,"Pai CH, Kelly JK and Meyers GL (1986) Experimental infection of infant rabbits with verotoxin-producing Escherichia coli. Infection and Immunity. 51 (1), 16â23."
"Dosing Experiments",171,"Chappell CL, Okhuysen PC, Langer-Curry R, Widmer G, Akiyoshi DE, Tanriverdi S and Tzipori S (2006) Cryptosporidium Hominis: Experimental Challenge of Healthy Adults. The American Journal of Tropical Medicine and Hygiene. 75 (5), 851â857."
"Dosing Experiments",172,"Chappell CL, Okhuysen PC, Langer-Curry R, Widmer G, Akiyoshi DE, Tanriverdi S and Tzipori S (2006) Cryptosporidium Hominis: Experimental Challenge of Healthy Adults. The American Journal of Tropical Medicine and Hygiene. 75 (5), 851â857."
"Dosing Experiments",173,"Okhuysen PC, Rich SM, Chappell CL, Grimes KA, Widmer G, Feng X and Tzipori S (2002) Infectivity of a Cryptosporidium parvum Isolate of Cervine Origin for Healthy Adults and Interferon-Î³ Knockout Mice. Journal of Infectious Diseases. 185 (9), 1320â1325."
"Dosing Experiments",174,"Okhuysen PC, Rich SM, Chappell CL, Grimes KA, Widmer G, Feng X and Tzipori S (2002) Infectivity of a Cryptosporidium parvum Isolate of Cervine Origin for Healthy Adults and Interferon-Î³ Knockout Mice. Journal of Infectious Diseases. 185 (9), 1320â1325."
"Dosing Experiments",175,"Blaser MJ, Duncan DJ, Warren GH and Wang W-LL (1983) Experimental Campylobacter jejuni Infection of Adult Mice. Infection and Immunity. 39 (2), 908â916."
"Dosing Experiments",176,"Blaser MJ, Duncan DJ, Warren GH and Wang W-LL (1983) Experimental Campylobacter jejuni Infection of Adult Mice. Infection and Immunity. 39 (2), 908â916."
"Dosing Experiments",177,"Blaser MJ, Duncan DJ, Warren GH and Wang W-LL (1983) Experimental Campylobacter jejuni Infection of Adult Mice. Infection and Immunity. 39 (2), 908â916."
"Dosing Experiments",178,"Tribble DR, Baqar S, Carmolli MP, Porter C, Pierce KK, Sadigh K, Guerry P, Larsson CJ, Rockabrand D, Ventone CH, Poly F, Lyon CE, Dakdouk S, Fingar A, Gilliland T, Daunais P, Jones E, Rymarchyk S, Huston C, Darsley M and Kirkpatrick BD (2009) Campylobacter jejuni Strain CG8421: A Refined Model for the Study of Campylobacteriosis and Evaluation of Campylobacter Vaccines in Human Subjects. Clinical Infectious Diseases. 49 (10), 1512â1519."
"Dosing Experiments",179,"Tribble DR, Baqar S, Scott DA, Oplinger ML, Trespalacios F, Rollins D, Walker RI, Clements JD, Walz S, Gibbs P, Burg EF, Moran AP, Applebee L and Bourgeois AL (2010) Assessment of the Duration of Protection in Campylobacter jejuni Experimental Infection in Humans. Infection and Immunity. 78 (4), 1750â1759."
"Dosing Experiments",180,"Black RE, Levine MM, Clements ML, Hughes TP and Blaser MJ (1988) Experimental Campylobacter jejuni Infection in Humans. Journal of Infectious Diseases. 157 (3), 472â479."
"Dosing Experiments",181,"Black RE, Levine MM, Clements ML, Hughes TP and Blaser MJ (1988) Experimental Campylobacter jejuni Infection in Humans. Journal of Infectious Diseases. 157 (3), 472â479."
"Dosing Experiments",182,"Chen L, Geys H, Cawthraw S, Havelaar A and Teunis P (2006) Dose Response for Infectivity of Several Strains of Campylobacter jejuni in Chickens. Risk Analysis. 26 (6), 1613â1621."
"Dosing Experiments",183,"Chen L, Geys H, Cawthraw S, Havelaar A and Teunis P (2006) Dose Response for Infectivity of Several Strains of Campylobacter jejuni in Chickens. Risk Analysis. 26 (6), 1613â1621."
"Dosing Experiments",184,"Chen L, Geys H, Cawthraw S, Havelaar A and Teunis P (2006) Dose Response for Infectivity of Several Strains of Campylobacter jejuni in Chickens. Risk Analysis. 26 (6), 1613â1621."
"Dosing Experiments",185,"Chen L, Geys H, Cawthraw S, Havelaar A and Teunis P (2006) Dose Response for Infectivity of Several Strains of Campylobacter jejuni in Chickens. Risk Analysis. 26 (6), 1613â1621."
"Dosing Experiments",186,"Chen L, Geys H, Cawthraw S, Havelaar A and Teunis P (2006) Dose Response for Infectivity of Several Strains of Campylobacter jejuni in Chickens. Risk Analysis. 26 (6), 1613â1621."
"Dosing Experiments",187,"Chen L, Geys H, Cawthraw S, Havelaar A and Teunis P (2006) Dose Response for Infectivity of Several Strains of Campylobacter jejuni in Chickens. Risk Analysis. 26 (6), 1613â1621."
"Dosing Experiments",188,"Chen L, Geys H, Cawthraw S, Havelaar A and Teunis P (2006) Dose Response for Infectivity of Several Strains of Campylobacter jejuni in Chickens. Risk Analysis. 26 (6), 1613â1621."
"Dosing Experiments",189,"Chen L, Geys H, Cawthraw S, Havelaar A and Teunis P (2006) Dose Response for Infectivity of Several Strains of Campylobacter jejuni in Chickens. Risk Analysis. 26 (6), 1613â1621."
"Dosing Experiments",190,"Chen L, Geys H, Cawthraw S, Havelaar A and Teunis P (2006) Dose Response for Infectivity of Several Strains of Campylobacter jejuni in Chickens. Risk Analysis. 26 (6), 1613â1621."
"Dosing Experiments",191,"Chen L, Geys H, Cawthraw S, Havelaar A and Teunis P (2006) Dose Response for Infectivity of Several Strains of Campylobacter jejuni in Chickens. Risk Analysis. 26 (6), 1613â1621."
"Dosing Experiments",192,"Chen L, Geys H, Cawthraw S, Havelaar A and Teunis P (2006) Dose Response for Infectivity of Several Strains of Campylobacter jejuni in Chickens. Risk Analysis. 26 (6), 1613â1621."
"Dosing Experiments",193,"Chen L, Geys H, Cawthraw S, Havelaar A and Teunis P (2006) Dose Response for Infectivity of Several Strains of Campylobacter jejuni in Chickens. Risk Analysis. 26 (6), 1613â1621."
"Dosing Experiments",194,"Chen L, Geys H, Cawthraw S, Havelaar A and Teunis P (2006) Dose Response for Infectivity of Several Strains of Campylobacter jejuni in Chickens. Risk Analysis. 26 (6), 1613â1621."
"Dosing Experiments",195,"Chen L, Geys H, Cawthraw S, Havelaar A and Teunis P (2006) Dose Response for Infectivity of Several Strains of Campylobacter jejuni in Chickens. Risk Analysis. 26 (6), 1613â1621."
"Dosing Experiments",196,"Chen L, Geys H, Cawthraw S, Havelaar A and Teunis P (2006) Dose Response for Infectivity of Several Strains of Campylobacter jejuni in Chickens. Risk Analysis. 26 (6), 1613â1621."
"Dosing Experiments",197,"Chen L, Geys H, Cawthraw S, Havelaar A and Teunis P (2006) Dose Response for Infectivity of Several Strains of Campylobacter jejuni in Chickens. Risk Analysis. 26 (6), 1613â1621."
"Dosing Experiments",198,"Chen L, Geys H, Cawthraw S, Havelaar A and Teunis P (2006) Dose Response for Infectivity of Several Strains of Campylobacter jejuni in Chickens. Risk Analysis. 26 (6), 1613â1621."
"Dosing Experiments",199,"Chen L, Geys H, Cawthraw S, Havelaar A and Teunis P (2006) Dose Response for Infectivity of Several Strains of Campylobacter jejuni in Chickens. Risk Analysis. 26 (6), 1613â1621."
"Dosing Experiments",200,"Chen L, Geys H, Cawthraw S, Havelaar A and Teunis P (2006) Dose Response for Infectivity of Several Strains of Campylobacter jejuni in Chickens. Risk Analysis. 26 (6), 1613â1621."
"Dosing Experiments",201,"Chen L, Geys H, Cawthraw S, Havelaar A and Teunis P (2006) Dose Response for Infectivity of Several Strains of Campylobacter jejuni in Chickens. Risk Analysis. 26 (6), 1613â1621."
"Dosing Experiments",202,"Chen L, Geys H, Cawthraw S, Havelaar A and Teunis P (2006) Dose Response for Infectivity of Several Strains of Campylobacter jejuni in Chickens. Risk Analysis. 26 (6), 1613â1621."
"Dosing Experiments",203,"Chen L, Geys H, Cawthraw S, Havelaar A and Teunis P (2006) Dose Response for Infectivity of Several Strains of Campylobacter jejuni in Chickens. Risk Analysis. 26 (6), 1613â1621."
"Dosing Experiments",204,"Cornick NA and Helgerson AF (2004) Transmission and Infectious Dose of Escherichia coli O157:H7 in Swine. Applied and Environmental Microbiology. 70 (9), 5331â5335."
"Dosing Experiments",205,"Bieber D, Ramer SW, Wu C-Y, Murray WJ, Tobe T, Fernandez R and Schoolnik GK (1998) Type IV Pili, Transient Bacterial Aggregates, and Virulence of Enteropathogenic Escherichia coli. Science. 280 (5372), 2114â2118."
"Dosing Experiments",206,"Levine MM, DuPont HL, Formal SB, Hornick RB, Takeuchi A, Gangarosa EJ, Snyder MJ and Libonati JP (1973) Pathogenesis of Shigella dysenteriae 1 (Shiga) Dysentery. Journal of Infectious Diseases. 127 (3), 261â270."
"Dosing Experiments",207,"Levine MM, Bergquist EJ, Nalin DR, Waterman DH, Hornick RB, Young CR and Sotman S (1978) Escherichia coli strains that cause diarrhoea but do not produce heat-labile or heat-stable enterotoxins and are non-invasive. Lancet. 1 (8074), 1119â1122."
"Dosing Experiments",208,"Levine MM, Bergquist EJ, Nalin DR, Waterman DH, Hornick RB, Young CR and Sotman S (1978) Escherichia coli strains that cause diarrhoea but do not produce heat-labile or heat-stable enterotoxins and are non-invasive. Lancet. 1 (8074), 1119â1122."
"Dosing Experiments",209,"Levine MM, Bergquist EJ, Nalin DR, Waterman DH, Hornick RB, Young CR and Sotman S (1978) Escherichia coli strains that cause diarrhoea but do not produce heat-labile or heat-stable enterotoxins and are non-invasive. Lancet. 1 (8074), 1119â1122."
"Dosing Experiments",210,"Levine MM, Bergquist EJ, Nalin DR, Waterman DH, Hornick RB, Young CR and Sotman S (1978) Escherichia coli strains that cause diarrhoea but do not produce heat-labile or heat-stable enterotoxins and are non-invasive. Lancet. 1 (8074), 1119â1122."
"Dosing Experiments",211,"Levine MM, Bergquist EJ, Nalin DR, Waterman DH, Hornick RB, Young CR and Sotman S (1978) Escherichia coli strains that cause diarrhoea but do not produce heat-labile or heat-stable enterotoxins and are non-invasive. Lancet. 1 (8074), 1119â1122."
"Dosing Experiments",212,"Levine MM, Bergquist EJ, Nalin DR, Waterman DH, Hornick RB, Young CR and Sotman S (1978) Escherichia coli strains that cause diarrhoea but do not produce heat-labile or heat-stable enterotoxins and are non-invasive. Lancet. 1 (8074), 1119â1122."
"Dosing Experiments",213,"Black RE, Brown KH, Becker S, Alim ARMA and Huq I (1982) Longitudinal Studies of Infectious Diseases and Physical Growth of Children in Rural Bangladesh Ii. Incidence of Diarrhea and Association with Known Pathogens. American Journal of Epidemiology. 115 (3), 315â324."
"Dosing Experiments",214,"Bartrand TA, Weir MH and Haas CN (2008) Dose-Response Models for Inhalation of Bacillus anthracis Spores: Interspecies Comparisons. Risk Analysis. 28 (4), 1115â1124."
"Dosing Experiments",215,"DuPont HL, Levine MM, Hornick RB and Formal SB (1989) Inoculum Size in Shigellosis and Implications for Expected Mode of Transmission. Journal of Infectious Diseases. 159 (6), 1126â1128."
"Dosing Experiments",216,"DuPont HL, Levine MM, Hornick RB and Formal SB (1989) Inoculum Size in Shigellosis and Implications for Expected Mode of Transmission. Journal of Infectious Diseases. 159 (6), 1126â1128."
"Dosing Experiments",217,"DuPont HL, Chappell CL, Sterling CR, Okhuysen PC, Rose JB and Jakubowski W (1995) The infectivity of Cryptosporidium parvum in healthy volunteers. The New England journal of medicine. 332 (13), 855â859."
"Dosing Experiments",218,"Strachan NJC, Doyle MP, Kasuga F, Rotariu O and Ogden ID (2005) Dose response modelling of Escherichia coli O157 incorporating data from foodborne and environmental outbreaks. International Journal of Food Microbiology. 103 (1), 35â47."
"Dosing Experiments",219,"Christy C, Madore HP, Pichichero ME, Gala C, Pincus P, Vosefski D, Hoshino Y, Kapikian A and Dolin R (1988) Field trial of rhesus rotavirus vaccine in infants. The Pediatric infectious disease journal. 7 (9), 645â650."
"Dosing Experiments",220,"Christy C, Madore HP, Pichichero ME, Gala C, Pincus P, Vosefski D, Hoshino Y, Kapikian A and Dolin R (1988) Field trial of rhesus rotavirus vaccine in infants. The Pediatric infectious disease journal. 7 (9), 645â650."
"Dosing Experiments",221,"Christy C, Madore HP, Pichichero ME, Gala C, Pincus P, Vosefski D, Hoshino Y, Kapikian A and Dolin R (1988) Field trial of rhesus rotavirus vaccine in infants. The Pediatric infectious disease journal. 7 (9), 645â650."
"Dosing Experiments",222,"Christy C, Madore HP, Pichichero ME, Gala C, Pincus P, Vosefski D, Hoshino Y, Kapikian A and Dolin R (1988) Field trial of rhesus rotavirus vaccine in infants. The Pediatric infectious disease journal. 7 (9), 645â650."
"Dosing Experiments",223,"McCullough NB and Elsele CW (1951) Experimental Human Salmonellosis: I. Pathogenicity of Strains of Salmonella meleagridis and Salmonella anatum Obtained from Spray-Dried Whole Egg. The Journal of Infectious Diseases. 88 (3), 278â289."
"Dosing Experiments",224,"McCullough NB and Elsele CW (1951) Experimental Human Salmonellosis: I. Pathogenicity of Strains of Salmonella meleagridis and Salmonella anatum Obtained from Spray-Dried Whole Egg. The Journal of Infectious Diseases. 88 (3), 278â289."
"Dosing Experiments",225,"McCullough NB and Elsele CW (1951) Experimental Human Salmonellosis: I. Pathogenicity of Strains of Salmonella meleagridis and Salmonella anatum Obtained from Spray-Dried Whole Egg. The Journal of Infectious Diseases. 88 (3), 278â289."
"Dosing Experiments",226,"McCullough NB and Elsele CW (1951) Experimental Human Salmonellosis: I. Pathogenicity of Strains of Salmonella meleagridis and Salmonella anatum Obtained from Spray-Dried Whole Egg. The Journal of Infectious Diseases. 88 (3), 278â289."
"Dosing Experiments",227,"McCullough NB and Elsele CW (1951) Experimental Human Salmonellosis: I. Pathogenicity of Strains of Salmonella meleagridis and Salmonella anatum Obtained from Spray-Dried Whole Egg. The Journal of Infectious Diseases. 88 (3), 278â289."
"Dosing Experiments",228,"McCullough NB and Elsele CW (1951) Experimental Human Salmonellosis: I. Pathogenicity of Strains of Salmonella meleagridis and Salmonella anatum Obtained from Spray-Dried Whole Egg. The Journal of Infectious Diseases. 88 (3), 278â289."
"Dosing Experiments",229,"McCullough NB and Elsele CW (1951) Experimental Human Salmonellosis: I. Pathogenicity of Strains of Salmonella meleagridis and Salmonella anatum Obtained from Spray-Dried Whole Egg. The Journal of Infectious Diseases. 88 (3), 278â289."
"Dosing Experiments",230,"McCullough NB and Elsele CW (1951) Experimental Human Salmonellosis: I. Pathogenicity of Strains of Salmonella meleagridis and Salmonella anatum Obtained from Spray-Dried Whole Egg. The Journal of Infectious Diseases. 88 (3), 278â289."
"Dosing Experiments",231,"McCullough NB and Elsele CW (1951) Experimental Human Salmonellosis: I. Pathogenicity of Strains of Salmonella meleagridis and Salmonella anatum Obtained from Spray-Dried Whole Egg. The Journal of Infectious Diseases. 88 (3), 278â289."
"Dosing Experiments",232,"Muller D, Edwards ML and Smith DW (1983) Changes in Iron and Transferrin Levels and Body Temperature in Experimental Airborne Legionellosis. The Journal of Infectious Diseases. 147 (2), 302â307."
"Dosing Experiments",233,"Fitzgeorge RB, Baskerville A, Broster M, Hambleton P and Dennis PJ (1983) Aerosol infection of animals with strains of Legionella pneumophila of different virulence: comparison with intraperitoneal and intranasal routes of infection. Epidemiology & Infection. 90 (01), 81â89."
"Dosing Experiments",234,"Breiman RF and Horwitz MA (1987) Guinea pigs sublethally infected with aerosolized Legionella pneumophila develop humoral and cell-mediated immune responses and are protected against lethal aerosol challenge. A model for studying host defense against lung infections caused by intracellular pathogens. The Journal of Experimental Medicine. 165 (3), 799â811."
"Dosing Experiments",235,"Saslaw S and Carlisle HN (1966) Aerosol infection of monkeys with Rickettsia rickettsii. Bacteriological Reviews. 30 (3), 636â645."
"Dosing Experiments",236,"Sammons LS, Kenyon RH and Pedersen CE (1976) Effect of vaccination schedule on immune response of Macaca mulatta to cell culture-grown Rocky Mountain spotted fever vaccine. Journal of Clinical Microbiology. 4 (3), 253â257."
"Dosing Experiments",237,"Meynell GG and Meynell EW (1958) The growth of micro-organisms in vivo with particular reference to the relation between dose and latent period. Epidemiology & Infection. 56 (03), 323â346."
"Dosing Experiments",238,"Meynell GG and Meynell EW (1958) The growth of micro-organisms in vivo with particular reference to the relation between dose and latent period. Epidemiology & Infection. 56 (03), 323â346."
"Dosing Experiments",239,"Meynell GG and Meynell EW (1958) The growth of micro-organisms in vivo with particular reference to the relation between dose and latent period. Epidemiology & Infection. 56 (03), 323â346."
"Dosing Experiments",240,"Hornick RB, Music SI, Wenzel R, Cash R, Libonati JP, Snyder MJ and Woodward TE (1971) The Broad Street pump revisited: response of volunteers to ingested cholera vibrios. Bulletin of the New York Academy of Medicine. 47 (10), 1181â1191."
"Dosing Experiments",241,"Diringer H, Roehmel J and Beekes M (1998) Effect of repeated oral infection of hamsters with scrapie. Journal of General Virology. 79 (3), 609â612."
"Dosing Experiments",242,"Jacquemot C, Cuche C, Dormont D and Lazarini F (2005) High Incidence of Scrapie Induced by Repeated Injections of Subinfectious Prion Doses. Journal of Virology. 79 (14), 8904â8908."
"Dosing Experiments",243,"Taylor DM, Woodgate SL and Atkinson MJ (1995) Inactivation of the bovine spongiform encephalopathy agent by rendering procedures. Veterinary Record. 137 (24), 605â610."
"Dosing Experiments",244,"John DT and Hoppe KL (1990) Susceptibility of Wild Mammals to Infection with Naegleria fowleri. The Journal of Parasitology. 76 (6), 865â868."
"Dosing Experiments",245,"John DT and Hoppe KL (1990) Susceptibility of Wild Mammals to Infection with Naegleria fowleri. The Journal of Parasitology. 76 (6), 865â868."
"Dosing Experiments",246,"Couch RB, Cate TR, Douglas RG, Gerone PJ and Knight V (1966) Effect of route of inoculation on experimental respiratory viral disease in volunteers and evidence for airborne transmission. Bacteriological Reviews. 30 (3), 517â529."
"Dosing Experiments",247,"Schiff GM, StefanoviÄ GM, Young EC, Sander DS, Pennekamp JK and Ward RL (1984) Studies of echovirus-12 in volunteers: determination of minimal infectious dose and the effect of previous infection on infectious dose. The Journal of infectious diseases. 150 (6), 858â866."
"Dosing Experiments",248,"Murphy BR, Clements ML, Madore HP, Steinberg J, OâDonnell S, Betts R, Demico D, Reichman RC, Dolin R and Maassab HF (1984) Dose Response of Cold-Adapted, Reassortant Influenza A/California/10/78 Virus (H1N1) in Adult Volunteers. Journal of Infectious Diseases. 149 (5), 816â816."
"Dosing Experiments",249,"Murphy BR, Clements ML, Tierney EL, Black RE, Stienberg J and Chanock RM (1985) Dose Response of Influenza A/Washington/897/80 (H3N2) Avian-Human Reassortant Virus in Adult Volunteers. The Journal of Infectious Diseases. 152 (1), 225â229."
"Dosing Experiments",250,"Fan S, Deng G, Song J, Tian G, Suo Y, Jiang Y, Guan Y, Bu Z, Kawaoka Y and Chen H (2009) Two amino acid residues in the matrix protein M1 contribute to the virulence difference of H5N1 avian influenza viruses in mice. Virology. 384 (1), 28â32."
"Dosing Experiments",251,"DeDiego ML, Pewe L, Alvarez E, Rejas MT, Perlman S and Enjuanes L (2008) Pathogenicity of severe acute respiratory coronavirus deletion mutants in hACE-2 transgenic mice. Virology. 376 (2), 379â389."
"Dosing Experiments",252,"Albuquerque ND, Baig E, Ma X, Zhang J, He W, Rowe A, Habal M, Liu M, Shalev I, Downey GP, Gorczynski R, Butany J, Leibowitz J, Weiss SR, McGilvray ID, Phillips MJ, Fish EN and Levy GA (2006) Murine Hepatitis Virus Strain 1 Produces a Clinically Relevant Model of Severe Acute Respiratory Syndrome in A/J Mice. Journal of Virology. 80 (21), 10382â10394."
"Dosing Experiments",253,"OâBrien R, Mackintosh CG, Bakker D, Kopecna M, Pavlik I and Griffin JFT (2006) Immunological and Molecular Characterization of Susceptibility in Relationship to Bacterial Strain Differences in Mycobacterium avium subsp. paratuberculosis Infection in the Red Deer (Cervus elaphus). Infection and Immunity. 74 (6), 3530â3537."
"Dosing Experiments",254,"NISBET DI, GILMOUR NJ and BROTHERSTON JG (1962) Quantitative studies of Mycobacterium johnei in tissues of sheep. III. Intestinal histopathology. Journal of comparative pathology. 72, 80â91."
"Dosing Experiments",255,"Badenoch PR, Johnson AM, Christy PE and Coster DJ (1990) Pathogenicity of Acanthamoeba and a Corynebacterium in the Rat Cornea. Archives of Ophthalmology. 108 (1), 107â112."
"Dosing Experiments",256,"Badenoch PR, Johnson AM, Christy PE and Coster DJ (1990) Pathogenicity of Acanthamoeba and a Corynebacterium in the Rat Cornea. Archives of Ophthalmology. 108 (1), 107â112."
"Dosing Experiments",257,"       Cerva L (1967-2) Intracerebral Inoculation of Experimental Animals in Pathogenetical Studies of Hartmannella Castellanii . Folia Parastologica. 14,171-176"
"Dosing Experiments",258,"       Cerva L (1967-2) Intracerebral Inoculation of Experimental Animals in Pathogenetical Studies of Hartmannella Castellanii . Folia Parastologica. 14,171-176"
"Dosing Experiments",259,"       Cerva L (1967-2) Intracerebral Inoculation of Experimental Animals in Pathogenetical Studies of Hartmannella Castellanii . Folia Parastologica. 14,171-176"
"Dosing Experiments",260,"       Cerva L (1967-2) Intracerebral Inoculation of Experimental Animals in Pathogenetical Studies of Hartmannella Castellanii . Folia Parastologica. 14,171-176"
"Dosing Experiments",261,"Culbertson CG, Ensminger PW and Overton WM (1966) Hartmannella (acanthamoeba). Experimental chronic, granulomatous brain infections produced by new isolates of low virulence. American journal of clinical pathology. 46 (3), 305â314."
"Dosing Experiments",262,"Culbertson CG, Ensminger PW and Overton WM (1966) Hartmannella (acanthamoeba). Experimental chronic, granulomatous brain infections produced by new isolates of low virulence. American journal of clinical pathology. 46 (3), 305â314."
"Dosing Experiments",263,"Culbertson CG, Ensminger PW and Overton WM (1966) Hartmannella (acanthamoeba). Experimental chronic, granulomatous brain infections produced by new isolates of low virulence. American journal of clinical pathology. 46 (3), 305â314."
"Dosing Experiments",264,"Culbertson CG, Ensminger PW and Overton WM (1966) Hartmannella (acanthamoeba). Experimental chronic, granulomatous brain infections produced by new isolates of low virulence. American journal of clinical pathology. 46 (3), 305â314."
"Dosing Experiments",265,"Day WC and Berendt RF (1972) Experimental Tularemia in Macaca mulatta: Relationship of Aerosol Particle Size to the Infectivity of Airborne Pasteurella tularensis. Infection and Immunity. 5 (1), 77â82."
"Dosing Experiments",266,"Quan SF, McManus AG and H. von Fintel (1956) Infectivity of Tularemia Applied to Intact Skin and Ingested in Drinking Water. Science. 123 (3204), 942â943."
"Dosing Experiments",267,"John DT and Hoppe KL (1990) Susceptibility of Wild Mammals to Infection with Naegleria fowleri. The Journal of Parasitology. 76 (6), 865â868."
"Dosing Experiments",268,"John DT and Hoppe KL (1990) Susceptibility of Wild Mammals to Infection with Naegleria fowleri. The Journal of Parasitology. 76 (6), 865â868."
"Dosing Experiments",269,"Rose JB and Haas CN (1999) A risk assessment framework for the evaluation of skin infections and the potential impact of antibacterial soap washing. American Journal of Infection Control. 27 (6), S26âS33."
"Dosing Experiments",270,"Lawin-BrÃ¼ssel CA, Refojo MF, Leong FL, Hanninen L and Kenyon KR (1993) Effect of Pseudomonas aeruginosa concentration in experimental contact lens-related microbial keratitis. Cornea. 12 (1), 10â18."
"Dosing Experiments",271,"Lawin-BrÃ¼ssel CA, Refojo MF, Leong FL, Hanninen L and Kenyon KR (1993) Effect of Pseudomonas aeruginosa concentration in experimental contact lens-related microbial keratitis. Cornea. 12 (1), 10â18."
"Dosing Experiments",272,"Hazlett LD, Rosen DD and Berk RS (1978) Age-Related Susceptibility to Pseudomonas aeruginosa Ocular Infections in Mice. Infection and Immunity. 20 (1), 25â29."
"Dosing Experiments",273,"Hazlett LD, Rosen DD and Berk RS (1978) Age-Related Susceptibility to Pseudomonas aeruginosa Ocular Infections in Mice. Infection and Immunity. 20 (1), 25â29."
"Dosing Experiments",274,"Hazlett LD, Rosen DD and Berk RS (1978) Age-Related Susceptibility to Pseudomonas aeruginosa Ocular Infections in Mice. Infection and Immunity. 20 (1), 25â29."
"Dosing Experiments",275,"Hazlett LD, Rosen DD and Berk RS (1978) Age-Related Susceptibility to Pseudomonas aeruginosa Ocular Infections in Mice. Infection and Immunity. 20 (1), 25â29."
"Dosing Experiments",276,"Hazlett LD, Rosen DD and Berk RS (1978) Age-Related Susceptibility to Pseudomonas aeruginosa Ocular Infections in Mice. Infection and Immunity. 20 (1), 25â29."
"Dosing Experiments",277,"Hazlett LD, Rosen DD and Berk RS (1978) Age-Related Susceptibility to Pseudomonas aeruginosa Ocular Infections in Mice. Infection and Immunity. 20 (1), 25â29."
"Dosing Experiments",278,"Hazlett LD, Rosen DD and Berk RS (1978) Age-Related Susceptibility to Pseudomonas aeruginosa Ocular Infections in Mice. Infection and Immunity. 20 (1), 25â29."
"Dosing Experiments",279,"Hazlett LD, Rosen DD and Berk RS (1978) Age-Related Susceptibility to Pseudomonas aeruginosa Ocular Infections in Mice. Infection and Immunity. 20 (1), 25â29."
"Dosing Experiments",280,"Smith MA, Takeuchi K, Anderson G, Ware GO, McClure HM, Raybourne RB, Mytle N and Doyle MP (2008) Dose-Response Model for Listeria monocytogenes-Induced Stillbirths in Nonhuman Primates. Infection and Immunity. 76 (2), 726â731."
"Dosing Experiments",281,"Williams D, Irvin EA, Chmielewski RA and Frank JF (May) Dose-Response of Listeria monocytogenes after Oral Exposure in Pregnant Guinea Pigs. Journal of Food Protection. 70 (5), 1122â1128."
"Dosing Experiments",282,"Golnazarian CA, Donnelly CW, Pintauro SJ and Howard DB Comparison of infectious dose of Listeria monocytogenes F5817 as determined for normal versus compromised C57B1/6J mice. Journal of food protection. 52 (10), 696â701."
"Dosing Experiments",283,"Golnazarian CA, Donnelly CW, Pintauro SJ and Howard DB Comparison of infectious dose of Listeria monocytogenes F5817 as determined for normal versus compromised C57B1/6J mice. Journal of food protection. 52 (10), 696â701."
"Dosing Experiments",284,"Czuprynski CJ, Faith NG and Steinberg H (2003) A/J Mice Are Susceptible and C57BL/6 Mice Are Resistant to Listeria monocytogenes Infection by Intragastric Inoculation. Infection and Immunity. 71 (2), 682â689."
"Dosing Experiments",285,"Czuprynski CJ, Faith NG and Steinberg H (2003) A/J Mice Are Susceptible and C57BL/6 Mice Are Resistant to Listeria monocytogenes Infection by Intragastric Inoculation. Infection and Immunity. 71 (2), 682â689."
"Dosing Experiments",286,"Golnazarian CA, Donnelly CW, Pintauro SJ and Howard DB Comparison of infectious dose of Listeria monocytogenes F5817 as determined for normal versus compromised C57B1/6J mice. Journal of food protection. 52 (10), 696â701."
"Dosing Experiments",287,"Audurier A, Pardon P, Marly J and Lantier F (1980) Experimental infection of mice with Listeria monocytogenes and L. innocua. Annales de microbiologie. 131B (1), 47â57."
"Dosing Experiments",288,"Lawin-BrÃ¼ssel CA, Refojo MF, Leong FL, Hanninen L and Kenyon KR (1993) Effect of Pseudomonas aeruginosa concentration in experimental contact lens-related microbial keratitis. Cornea. 12 (1), 10â18."
"Dosing Experiments",289,"Lawin-BrÃ¼ssel CA, Refojo MF, Leong FL, Hanninen L and Kenyon KR (1993) Effect of Pseudomonas aeruginosa concentration in experimental contact lens-related microbial keratitis. Cornea. 12 (1), 10â18."
Echovirus,1,http://en.wikipedia.org/wiki/Echovirus
Echovirus,2,"Modlin, J. F. (1986). ""[http://www.jstor.org/stable/4453981 Perinatal Echovirus Infection: Insights from a Literature Review of 61 Cases of SeriousInfection and 16 Outbreaks in Nurseries]."" Reviews of Infectious Diseases '''8'''(6): 918-926."
Echovirus,4,"[http://emedicine.medscape.com/article/963458-overview#showall Medscape]"
"Endamoeba coli: Dose Response Models",1,"[http://www.cdc.gov/parasites/nonpathprotozoa/ CDC]"
"Endamoeba coli: Dose Response Models",3,"[http://www.cdc.gov/parasites/nonpathprotozoa/ CDC]"
"Entamoeba coli",1,"

=Case Fatality Ratios=
Case fatality rates associated with amebic colitis range from 1.9%-9.1%. Amebic colitis evolves to fulminant necrotizing colitis or rupture in approximately 0.5% of cases; in such cases, the mortality rate jumps to greater than 40%. AristizÃ¡bal H, Acevedo J, Botero M. Fulminant amebic colitis. World J Surg. Mar-Apr 1991;15(2):216-21 [http://www.springerlink.com/content/h55334242p614017/fulltext.pdf Full Text] The mortality rate due to amebic liver abscess has fallen to 1-3% in the last century following the introduction of effective medical treatment. Nevertheless, amebic liver abscess is complicated by sudden intraperitoneal rupture in 2-7% of patients, leading to a higher mortality rateStanley SL Jr. Amoebiasis. Lancet. Mar 22 2003;361(9362):1025-34 

=Burden of Disease=
Asymptomatic intestinal amebiasis occurs in 90% of infected individuals. However, only 4%-10% of individuals with asymptomatic amebiasis who were monitored for one year eventually developed colitis or extraintestinal disease Fotedar R, Stark D, Beebe N, et al. Laboratory diagnostic techniques for Entamoeba species. Clin Microbiol Rev. Jul 2007;20(3):511-32 [http://cmr.asm.org/cgi/reprint/20/3/511 Full Text] The overall prevalence of amebiasis is approximately 4% in the United States Entamoeba species infect approximately 10% of the world's population

====Duration of Infectiousness and disease====
====Symptomology====
====Latency====
====Asymptomatic Rates====
====Excretion Rates (see Exposure) ====
====Immunity====

=Microbiology=
A non-pathogenic species of Entamoeba that frequently exists as a commensal parasite in the human gastrointestinal tract

=Environmental Survival=
Survive weeks to months in the external environment

=Recommended Dose Response Model=
[[Endamoeba coli: Dose Response Models]]  Beta-Poisson, Î± is 0.10, N50 is 340.78  [[File:Betapoisson_model.jpg|thumb|left|300px]]








===References===
http://www.cdc.gov/parasites/nonpathprotozoa/biology.html 
http://en.wikipedia.org/wiki/Entamoeba_coli 
http://www.cdc.gov/parasites/nonpathprotozoa/ 
[http://emedicine.medscape.com/article/996092-overview#showall Medscape Pediatric Amebiasis]
[[Category:Agent Overview]][[Category:Protozoan]]"
"Entamoeba coli",2,"AristizÃ¡bal H, Acevedo J, Botero M. Fulminant amebic colitis. World J Surg. Mar-Apr 1991;15(2):216-21 [http://www.springerlink.com/content/h55334242p614017/fulltext.pdf Full Text]"
"Entamoeba coli",3,"Stanley SL Jr. Amoebiasis. Lancet. Mar 22 2003;361(9362):1025-34"
"Entamoeba coli",4,"Fotedar R, Stark D, Beebe N, et al. Laboratory diagnostic techniques for Entamoeba species. Clin Microbiol Rev. Jul 2007;20(3):511-32 [http://cmr.asm.org/cgi/reprint/20/3/511 Full Text]"
Enteroviruses,1,"ZHANG Jing, SUN JunLing, CHANG ZhaoRui, ZHANG WeiDong, WANG ZiJun, and FENG ZiJian. (2011) Characterization of Hand, Foot, and Mouth Disease in China between 2008 and 2009. Biomed Environ Sci, 24(3): 214â221 [http://www.sciencedirect.com.proxy2.cl.msu.edu/science?_ob=MiamiImageURL&_cid=277239&_user=1111158&_pii=S0895398811600421&_check=y&_origin=&_coverDate=30-Jun-2011&view=c&wchp=dGLbVlk-zSkWb&md5=c0d0f376dab5e00dce8a06a69518b769/1-s2.0-S0895398811600421-main.pdf Full Text]"
Enteroviruses,2,http://emedicine.medscape.com/article/217146-overview#showall
Enteroviruses,5,http://en.wikipedia.org/wiki/Enterovirus
"Escherichia coli",1,"[http://www.azdhs.gov/phs/edc/edrp/pdf/escherichiacoliset.pdf Arizona Department of Health Services]"
"Escherichia coli",2,"[http://emedicine.medscape.com/article/217485-overview#showall Medscape Page]"
"Escherichia coli",5,"[http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5813a2.htm CDC MMWR Apr 10, 2009]"
"Escherichia coli",6,"[http://www.cdc.gov/nczved/divisions/dfbmd/diseases/ecoli_o157h7/#symptoms CDC Page] "
"Escherichia coli",7,"[http://en.wikipedia.org/wiki/Escherichia_coli Wikipedia Page]"
"Escherichia coli: Dose Response Models",1,"Kaper JB, Nataro JP & Mobley HL (2004) Pathogenic Escherichia coli. Nature Reviews. Microbiology. 2(2), pp.123-140. [http://www.nature.com/nrmicro/journal/v2/n2/pdf/nrmicro818.pdf Full text]"
"Escherichia coli: Dose Response Models",2,"Nataro JP & Kaper JB (1998) Diarrheagenic Escherichia coli. Clinical Microbiology Reviews. 11(1), pp.142-201. [http://cmr.asm.org/cgi/reprint/11/1/142 Full text] "
"Escherichia coli: Dose Response Models",3,"Qadri F, et al. (2005) Enterotoxigenic Escherichia coli in developing countries: epidemiology, microbiology, clinical features, treatment, and prevention. Clinical Microbiology Reviews. 18(3), pp.465-483. [http://cmr.asm.org/cgi/reprint/18/3/465 Full text] "
"Escherichia coli: Dose Response Models",4,"WennerÃ¥s C & Erling V (2004) Prevalence of enterotoxigenic Escherichia coli-associated diarrhoea and carrier state in the developing world. Journal of Health, Population, and Nutrition. 22(4), pp.370-382. [http://imsear.hellis.org/handle/123456789/542 Abstract]"
"Escherichia coli: Dose Response Models",10,"Levine MM, et al. (1980) Lack of person-to-person transmission of enterotoxigenic Escherichia coli despite close contact. American Journal of Epidemiology. 111(3), pp.347-355. [http://aje.oxfordjournals.org/content/111/3/347.full.pdf+html Full text]"
"Escherichia coli: Dose Response Models",12,"Haas CN, Rose JB & Gerba CP (1999) Quantitative Microbial Risk Assessment. John Wiley & Sons, Inc."
"Escherichia coli: Dose Response Models",13,"Ferguson WW & June RC (1952) Experiments on feeding adult volunteers with Escherichia coli 111, B4, a coliform organism associated with infant diarrhea. American Journal of Hygiene. 55(2), pp.155-169. [http://aje.oxfordjournals.org/content/55/2/155.full.pdf+html Full text]"
"Escherichia coli: Dose Response Models",16,"Powell MR (2000) Dose-response envelope for Escherichia coli O157:H7. Quantitative Microbiology. 2, pp.141-163. [http://www.springerlink.com/content/k3t3768n75w16246/fulltext.pdf Full text]"
"Escherichia coli: Dose Response Models",17,"Levine MM, et al. (1978) Escherichia coli strains that cause diarrhoea but do not produce heat-labile or heat-stable enterotoxins and are non-invasive. Lancet. 1(8074), pp.1119-1122. [http://www.sciencedirect.com/science/article/pii/S0140673678902994 Abstract]"
"Escherichia coli: Dose Response Models",18,"Bieber D, et al. (1998) Type IV pili, transient bacterial aggregates, and virulence of enteropathogenic Escherichia coli. Science (New York, N.Y.). 280(5372), pp.2114-2118. [http://www.sciencemag.org/content/280/5372/2114.full Full text]"
"Escherichia coli enterohemorrhagic (EHEC): Dose Response Models",1,"Strachan NJC et al. (2005) Dose response modelling of Escherichia coli O157 incorporating data from foodborne and environmental outbreaks. International Journal of Food Microbiology. 103(1), pp.35-47. [http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6T7K-4FNCW2P-2-7&_cdi=5061&_user=1111158&_pii=S0168160505000693&_origin=gateway&_coverDate=08%2F15%2F2005&_sk=998969998&view=c&wchp=dGLbVzW-zSkzk&md5=bc35dbff2f730b099c8a5dabd9fe1baa&ie=/sdarticle.pdf Full Text]"
"Escherichia coli enterohemorrhagic (EHEC): Dose Response Models",2,"Auld H, MacIver D & Klaassen J (2004) Heavy rainfall and waterborne disease outbreaks: the Walkerton example. Journal of Toxicology and Environmental Health. Part A. 67(20-22), pp.1879-1887. [http://docserver.ingentaconnect.com/deliver/connect/tandf/15287394/v67n20/s25.pdf?expires=1302533913&id=62221784&titleid=1278&accname=MICHIGAN+STATE+UNIVERSITY&checksum=2B7EDA587378C6DB157082DB0FDF38BC Full Text]"
"Escherichia coli enterohemorrhagic (EHEC): Dose Response Models",3,"Kaper JB, Nataro JP & Mobley HL (2004) Pathogenic Escherichia coli. Nature Reviews. Microbiology. 2(2), pp.123-140. [http://www.nature.com/nrmicro/journal/v2/n2/full/nrmicro818.html Full Text]"
"Escherichia coli enterohemorrhagic (EHEC): Dose Response Models",4,"Nataro JP & Kaper JB (1998) Diarrheagenic Escherichia coli. Clinical Microbiology Reviews. 11(1), pp.142-201. [http://cmr.asm.org/cgi/reprint/11/1/142 Full Text]"
"Escherichia coli enterohemorrhagic (EHEC): Dose Response Models",5,"Teunis P, Takumi K & Shinagawa K (2004) Dose response for infection by Escherichia coli O157:H7 from outbreak data. Risk Analysis: An Official Publication of the Society for Risk Analysis. 24(2), pp.401-407. [http://onlinelibrary.wiley.com/doi/10.1111/j.0272-4332.2004.00441.x/pdf Full Text]"
"Escherichia coli enterohemorrhagic (EHEC): Dose Response Models",7,"Haas CN et al. (2000)  Development of a dose-response relationship for Escherichia coli O157:H7. International Journal of Food Microbiology. 56(2-3), pp.153-159. [http://smas.chemeng.ntua.gr/miram/files/publ_47_9_1_2004.pdf Full Text]"
"Escherichia coli enterohemorrhagic (EHEC): Dose Response Models",9,"Teunis P, Takumi K & Shinagawa K (2004) Dose response for infection by Escherichia coli O157:H7 from outbreak data. Risk Analysis: An Official Publication of the Society for Risk Analysis. 24(2), pp.401-407. [http://onlinelibrary.wiley.com/doi/10.1111/j.0272-4332.2004.00441.x/pdf Full Text]"
"Escherichia coli enterohemorrhagic (EHEC): Dose Response Models",10,"Powell MR (2000) Dose-response envelope for Escherichia coli O157:H7. Quantitative Microbiology. 2, pp.141-163. [http://www.springerlink.com/content/k3t3768n75w16246/fulltext.pdf Full Text]"
"Escherichia coli enterohemorrhagic (EHEC): Dose Response Models",13,"Strachan, N.J.C. et al., 2005. Dose response modelling of Escherichia coli O157 incorporating data from foodborne and environmental outbreaks. International Journal of Food Microbiology, 103(1), pp.35-47."
"Francisella tularensis",1,"[http://turkishjournalpediatrics.org/pediatrics/pdf/pdf_TJP_1033.pdf Turkish Journal of Pediatrics]"
"Francisella tularensis",2,"[http://emedicine.medscape.com/article/787109-overview#showall Medscape Page]"
"Francisella tularensis",3,"Ellis, J., Oyston, P. C. F., Green, M., & Titball, R. W. (2002). Tularemia. Clinical Microbiology Reviews, 15(4), 631â646. doi:10.1128/CMR.15.4.631-646.2002 [http://www.cmr.asm.org/content/15/4/631.full.pdf+html Full Text]"
"Francisella tularensis",5,"[http://www.cdc.gov/tularemia/signssymptoms/ CDC Page]"
"Francisella tularensis",6,"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3109299/?tool=pubmed PubMed"
"Francisella tularensis",7,"TÃ¤rnvik, A., & Berglund, L. (2003). Tularaemia. European Respiratory Journal, 21(2), 361â373. doi:10.1183/09031936.03.00088903[http://erj.ersjournals.com/content/21/2/361.full#sec-17 Full Text]"
"Francisella tularensis: Dose Response Models",1,"Titball, R. W. and A. Sjostedt (2003). ""Francisella tularensis: an overview."" American Society for Microbiology News '''69'''(11): 558-563."
"Francisella tularensis: Dose Response Models",2,"World Health Organization (1970). Health Aspects of Chemical and Biological Weapons. Geneva, Switzerland, World Health Organization."
"Francisella tularensis: Dose Response Models",3,"Christopher, G. W., T. J. Cieslak, J. A. Pavlin and E. M. Eitzen (1997). ""[http://jama.ama-assn.org/content/278/5/412.abstract Biological warfare: a historical perspective.]"" JAMA (Journal of the American Medical Association) '''278''': 412-417."
"Francisella tularensis: Dose Response Models",4,"Kaufmann, A. F., M. I. Meltzer and G. P. Schmid (1997). ""[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2627615/ The economic impact of a bioterrorist attack: are prevention and post-attack intervention programs justifiable?]"" Emerging Infectious Diseases '''2''': 83-94."
"Francisella tularensis: Dose Response Models",5,"Stuart, B. M. and R. L. Pullen (1945). ""[http://journals.lww.com/amjmedsci/Citation/1945/08000/Tularemic_Pneumonia__Review_of_American_Literature.13.aspx Tularemic pneumonia: Review of American literature and report of 15 additional cases.]"" American Journal of the Medical Sciences '''210''': 223-236.
"
"Francisella tularensis: Dose Response Models",6,"Saslaw, S., H. T. Eigelsbach, J. A. Prior, H. E. Wilson and S. Carhart (1961). ""[http://archinte.ama-assn.org/cgi/reprint/107/5/702 Tularemia vaccine study. II. Respiratory challenge.]"" Arch Intern Med. '''107''': 702-714."
"Francisella tularensis: Dose Response Models",7,"Saslaw, S., H. T. Eigelsbach, H. E. Wilson, J. A. Prior and S. Carhart (1961). ""[http://archinte.ama-assn.org/cgi/reprint/107/5/689 Tularemia vaccine study, I: intracutaneous challenge.]"" Arch Intern Med '''107''': 121-133.
"
"Francisella tularensis: Dose Response Models",8,"Day, W. C. and R. F. Berendt (1972). ""[http://iai.asm.org/cgi/content/abstract/5/1/77 Experimental Tularemia in Macaca mulatta: Relationship of Aerosol Particle Size to the Infectivity of Airborne Pasteurella tularensis.]"" Infection and Immunity '''5'''(1): 77-82."
"Francisella tularensis: Dose Response Models",9,"Quan, S. F., A. G. McManus and H. von Fintel (1956). ""[http://www.jstor.org.proxy2.cl.msu.edu/stable/1750157?&Search=yes&list=hide&searchUri=%2Fsici%3Fsici%3D0036-8075%25281956%2529123%253A3204%253C942%253AIOTATI%253E2.0.CO%253B2-S%26origin%3DISI&prevSearch=&item=1&ttl=2&returnArticleService=showFullText Infectivity of Tularemia Applied to Intact Skin and Ingested in Drinking Water.]"" Science '''123''': 942-943.
"
"Giardia duodenalis",1,"[http://en.wikipedia.org/wiki/Giardia Wiki]"
"Giardia duodenalis",2,"[http://en.wikipedia.org/wiki/Giardia Wiki]"
"Giardia duodenalis",3,"[http://emedicine.medscape.com/article/176718-overview#showall Medscape]"
"Giardia duodenalis",5,"[http://www.cdc.gov/parasites/giardia/ CDC MMWR]"
"Giardia duodenalis",6,"[http://www.cdc.gov/parasites/giardia/ CDC]"
"Indoor Air Pollution",8,"
Abdul-Wahab, Sabah A. Sick Building Syndrome: In Public Buildings and Workplaces. Berlin: Springer, 2011. Internet resource."
"Indoor Air Pollution",9,"Pluschke, P. ''Indoor Air Pollution''. The Handbook of Environmental Chemistry, Volume 4F, 2004. Internet resource"
"Indoor Air Pollution",10,"Rodrigues, Eliane R, and Jorge A. Achcar. Applications of Discrete-Time Markov Chains and Poisson Processes to Air Pollution Modeling and Studies. New York, NY: Springer, 2013. Internet resource."
"Indoor Air Pollution",11,"Williams PRD (2000) The risk analysis framework: Risk assessment, risk management, and risk
communication. In Spengler JD, Samet JM, McCarthy JF (Ed.) Indoor Air Quality Handbook.
McGraw-Hill, New York, NY."
"Influenza virus",1,"[http://emedicine.medscape.com/article/219557-overview#showall emedicine.medscape]"
"Influenza virus",2,"Heron M, Hoyert D, Murphy SL, Xu J, Kochanek KD, Tejada-Vera B. Division of Vital Statistics. Deaths: Final Data for 2006. National Vital Statistics Reports. National Center for Health Statistics. [http://www.cdc.gov/nchs/data/nvsr/nvsr57/nvsr57_14.pdf Full Text]"
"Influenza virus",3,"Xu J, Kochanek KD, Murphy SL, Tejada-Vera B. Division of Vital Statistics. Deaths: Final Data for 2007. National Vital Statistics Reports. National Center for Health Statistics.  [http://www.cdc.gov/NCHS/data/nvsr/nvsr58/nvsr58_19.pdf Full Text]"
"Influenza virus",5," http://jvi.asm.org/content/84/8/3974.long "
"Influenza virus",7," http://www.ncbi.nlm.nih.gov/pubmed/18039138 "
"Influenza virus",8," http://www.cdc.gov/flu/index.htm "
"Influenza virus",9," CDC http://www.cdc.gov/flu/index.htm "
"Lassa virus",1,"http://www.cdc.gov/ncidod/dvrd/spb/mnpages/dispages/Fact_Sheets/Lassa_Fever_Fact_Sheet.pdf "
"Lassa virus",2,"[http://emedicine.medscape.com/article/830594-overview#showall emachine.medscape]"
"Lassa virus",3,"[http://en.wikipedia.org/wiki/Lassa_fever Wikipedia]"
"Legionella pneumophila",1,"Health Protection Agency. âModes of Infection: Aerosolisation.â Web. 21 May 2012. http://www.hpa.org.uk/webw/HPAweb&HPAwebStandard/HPAweb_C/1204186178183?p=1191942128209
"
"Legionella pneumophila",2,"Benin, Andrea L, Robert F Benson, and Richard E Besser. âTrends in Legionnaires Disease, 1980â1998: Declining Mortality and New Patterns of Diagnosis.â Clinical Infectious Diseases 35.9 (2002): 1039â1046. Web. 21 May 2012."
"Legionella pneumophila",4,"Den Boer, Jeroen W. âA Large Outbreak of Legionnairesâ Disease at a Flower Show, the Netherlands, 1999.â Emerging Infectious Diseases 8.1 (2002): 37â43. Web. 9 May 2012."
"Legionella pneumophila",5,"Center for Disease Control. ""Patient Facts: Learn More about Legionnaires' disease"". http://www.cdc.gov/legionella/patient_facts.htm"
"Legionella pneumophila",6,"Center for Disease Control. ""Morbidity and Mortality Weekly Report: Legionellosis"". http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6032a3.htm "
"Legionella pneumophila",8,"Marston BJ, Lipman HB, Breiman RF. Surveillance for legionnairesâ disease: risk factors for morbidity and mortality. Arch Intern Med 1994; 154:2417â22."
"Legionella pneumophila",11," Madigan M; Martinko J (editors). (2005). Brock Biology of Microorganisms (11th ed.). Prentice Hall. ISBN 0-13-144329-1."
"Legionella pneumophila",12,"Heuner K; Swanson M (editors). (2008). Legionella: Molecular Microbiology. Caister Academic Press. ISBN 978-1-904455-26-4."
"Legionella pneumophila",13,"Fields BS, Benson RF, Besser RE. Legionella and legionnairesâ disease: 25 years of investigation. Clin Microbiol Rev 2002; 15:506â26."
"Legionella pneumophila: Dose Response Models",1,"Armstrong, T. W. (2005). A Quantitative Microbial Risk Assessment Model for Human Inhalation Exposure to Legionella. Department of Civil, Architectural and Environmental Engineering. Philadelphia, Drexel University. '''PhD thesis'''. ""[https://idea.library.drexel.edu/islandora/object/idea%3A615]"" ."
"Legionella pneumophila: Dose Response Models",2,"Muller, D., M. L. Edwards and D. W. Smith (1983). ""[http://www.jstor.org/stable/30115078 Changes in iron and transferrin levels and body temperature in experimental airborne legionellosis.]"" Journal of Infectious Diseases '''147''': 302-307."
"Legionella pneumophila: Dose Response Models",3,"Fitzgeorge, R. B., A. Baskerville, M. Broster, P. Hambleton and P. J. Dennis (1983). ""[http://journals.cambridge.org/action/displayAbstract?fromPage=online&aid=5838696 Aerosol infection of animals with strains of Legionella pneumophila of different virulence: comparison with intraperitoneal and intranasal routes of infection.]"" Epidemiology and Infection '''90'''(1): 81-89."
"Legionella pneumophila: Dose Response Models",4,"Breiman, R. F. and M. A. Horwitz (1987). ""[http://jem.rupress.org/content/165/3/799.abstract Guinea pigs sublethally infected with aerosolized Legionella pneumophila develop humoral and cell-mediated immune responses and are protected against lethal aerosol challenge. A model for studying host defense against lung infections caused by intracellular pathogens.]"" Journal of experimental medicine '''165'''(3): 799-811."
"Listeria monocytogenes (Infection): Dose Response Models",1,"[http://www.cdc.gov/listeria/ CDC]"
"Listeria monocytogenes (Infection): Dose Response Models",2,"[http://textbookofbacteriology.net/ Todar]"
"Listeria monocytogenes (Infection): Dose Response Models",7,"Haas CN, Thayyar-Madabusi A, et al. (1999) Development and Validation of Dose-Response Relationship for Listeria monocytogenes. Quantitative Microbiology 1(1): 89-102."
"Methods of Analysis",1,"Viscusi WK and Aldy JE (2003) The value of a statistical life: A critical review of market estimates   throughout the world. Journal of Risk and Uncertainty. 27 (1), 5â76."
"Methods of Analysis",2,"Gurian PL, Small MJ, Lockwood JR and Schervish MJ (2001) Benefit-cost estimation for alternative drinking water maximum   contaminant levels. Water Resources Research. 37 (8), 2213â2226."
"Methods of Analysis",4," [http://whqlibdoc.who.int/publications/2001/924154533x_chap15.pdf 2001 World Health Organization (WHO). Water Quality: Guidelines, Standards and Health. Edited by
Lorna Fewtrell and Jamie Bartram. Published by IWA Publishing, London, UK. ISBN: 1 900222 28 0] "
"Methods of Analysis",6," [http://www.who.int/quantifying_ehimpacts/publications/en/wsh00-10.pdf  Considerations in evaluating the cost-effectiveness of environmental health interventionsons,WHO 2000] "
"Methods of Analysis",7," [http://www.who.int/quantifying_ehimpacts/publications/en/wsh00-10.pdf  Considerations in evaluating the cost-effectiveness of environmental health interventionsons,WHO 2000] "
"Mycobacterium avium: Dose Response Models",1,"[Ayele WY, Svastova P, et al. (2005) Mycobacterium avium Subspecies paratuberculosis Cultured from Locally and Commercially Pasteurized Cow's Milk in the Czech Republic. Applied and Environmental Microbiology 71(3): 1210-1214. Ayele]"
"Mycobacterium avium: Dose Response Models",2,"OâBrien R, Mackintosh CG, Bakker D, Kopecna M, Pavlik I, Griffin JF, (2006) Immunological and molecular characterization of susceptibility in relationship to bacterial strain differences in Mycobacterium avium subsp. paratuberculosis infection in the red deer (Cervus elaphus). Infection and Immunity 74, 3530â3537. [http://www.ncbi.nlm.nih.gov/pubmed/16714585 Full Text]"
"Mycobacterium avium: Dose Response Models",3,"Brotherston JG, Gilmour NJ, Samuel J, 1961. Quantitative studies of Mycobacterium johnei in the tissues of sheep. Journal of Comparative Pathology 71, 286â299. [http://www.ncbi.nlm.nih.gov/pubmed/14317616 Full Text]"
"Naegleria fowleri",1,"[http://en.wikipedia.org/wiki/Naegleria_fowleri Wiki]"
"Naegleria fowleri",2,"[http://www.cdc.gov/parasites/naegleria/ CDC]"
"Naegleria fowleri",4,"[http://emedicine.medscape.com/article/972044-overview Medscape]"
"Old Main Page",1,"This is the citation."
"Old Main Page",2,"E. Miller, The Sun, (New York: Academic Press, 2005), 23-5."
"Poliovirus: Dose Response Models",3,"Koprowski H (1956) Immunization against Poliomyelitis with Living Attenuated Virus. ''The American Journal of Tropical Medicine and Hygiene'' 5(3), 440-452."
"Poliovirus: Dose Response Models",6,"Sabin AB (1955) Behaviour Of Chimpanzee-Avirulent Poliomyelitis Viruses In Experimentally Infected Human Volunteers. ''The British Medical Journal'' 2(4932), 160-162."
"PrP prion",1,"[http://www.cdc.gov/ncidod/dvrd/prions/ CDC]"
"PrP prion",2,"[http://emedicine.medscape.com/article/1168941-overview#showall Medscape]"
"PrP prion",3,"John Collinge, Jerome Whitfi eld, Edward McKintosh, John Beck, Simon Mead, Dafydd J Thomas, Michael P Alpers. (2006) Kuru in the 21st centuryâan acquired human prion disease
with very long incubation periods. Lancet. 367: 2068â74. [http://www.sciencedirect.com.proxy1.cl.msu.edu/science?_ob=MiamiImageURL&_cid=271074&_user=1111158&_pii=S0140673606689307&_check=y&_origin=&_coverDate=30-Jun-2006&view=c&wchp=dGLbVBA-zSkWA&md5=4cf4946d5669da97178c506ee474f5a9/1-s2.0-S0140673606689307-main.pdf Full Text]"
Rhinovirus,1,"[http://en.wikipedia.org/wiki/Rhinovirus Wikipedia]"
Rhinovirus,2,"Justin Lessler, Nicholas G Reich, Ron Brookmeyer, Trish M Perl, Kenrad E Nelson, Derek A T Cummings. 2009. Incubation periods of acute respiratory viral infections: a systematic review. Lancet Infect Dis. 9: 291-300. [http://www.sciencedirect.com.proxy2.cl.msu.edu/science?_ob=MiamiImageURL&_cid=272254&_user=1111158&_pii=S1473309909700696&_check=y&_origin=gateway&_coverDate=31-May-2009&view=c&wchp=dGLzVlS-zSkWz&md5=f0c0d02d3cf7ae22920f8e6adf57be70/1-s2.0-S1473309909700696-main.pdf Full Text]"
Rhinovirus,3,"Janice K. Louie, Shigeo Yagi, Fritzi A. Nelson, David Kiang, Carol A. Glaser, Jon Rosenberg, Christine K. Cahill, and David P. Schnurr. (2005) Rhinovirus Outbreak in a Long Term Care Facility for Elderly Persons Associated with Unusually High Mortality. CID. 41: 262-265 [http://cid.oxfordjournals.org/content/41/2/262.full.pdf+html Full text]"
Rhinovirus,4,"Philip A. Chan, Leonard A. Mermel, Sarah B. Andrea, Russell McCulloh, John P. Mills, Ignacio Echenique, Emily Leveen, Natasha Rybak, Cheston Cunha, Jason T. Machan, Terrance T. Healey,
and Kimberle C. Chapin. (2011) Distinguishing Characteristics between Pandemic 2009â2010 Influenza A (H1N1) and Other Viruses in Patients Hospitalized with Respiratory Illness. PLoS ONE. 6(9) [http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0024734 Full text]"
Rhinovirus,5,"[http://emedicine.medscape.com/article/971592-overview#showall Medscape]"
"Rickettsia rickettsii",1,"Burgdorfer, W. 1988. Ecological and epidemiological considerations of Rocky Mountain spotted fever and scrub typhus, p. 33-50. In D. H. Walker (ed.), Biology of rickettsial diseases, vol. 1. CRC Press, Boca Raton, Fla."
"Rickettsia rickettsii",2,"McDade, J. E., and V. F. Newhouse. 1986. Natural history of Rickettsia rickettsii. Annu. Rev. Microbiol. 40:287-309."
"Rickettsia rickettsii",3,"Center for Disease Control. ""Rocky Mountain Spotted Fever"". http://www.cdc.gov/rmsf/"
"Rickettsia rickettsii",4,"Walker, D H. âRocky Mountain Spotted Fever: a Disease in Need of Microbiological Concern.â Clinical Microbiology Reviews 2.3 (1989): 227â240. "
"Rickettsia rickettsii",5,"Saslaw, S. and Carlisle, H.N. (1966) Aerosol Infection of Monkeys with Rickettsia Rickettsi. Bacteriological Reviews 30(3): 636-644 [http://mmbr.asm.org/content/30/3/636.full.pdf Full text]"
"Rickettsia rickettsii",6,"Center for Disease Control. ""Rocky Mountain Spotted Fever: Symptoms, Diagnosis, and Treatment"". http://www.cdc.gov/rmsf/symptoms/index.html"
"Rickettsia rickettsii",7,"Hattwick MA, OâBrien RJ, Hanson BF (1976) Rocky Mountain spotted fever: epidemiology of an increasing problem. Ann Intern Med 84(6):732â739"
"Rickettsia rickettsii",8,"Botelho-Nevers, E, and D Raoult. âHost, Pathogen and Treatment-related Prognostic Factors in Rickettsioses.â European Journal of Clinical Microbiology & Infectious Diseases: Official Publication of the European Society of Clinical Microbiology 30.10 (2011): 1139â1150. Web. 23 May 2012."
"Rickettsia rickettsii",10,"Helmick CG, Bernard KW, DâAngelo LJ (1984) Rocky Mountain spotted fever: clinical, laboratory, and epidemiological features of 262 cases. J Infect Dis 150(4):480â488"
"Rickettsia rickettsii",11,"Del Fiol, FD (Del Fiol, Fernando de Sa), Junqueira, FM (Junqueira, Fabio Miranda), da Rocha, MCP (Pereira da Rocha, Maria Carolina), de Toledo, MI (de Toledo, Maria Ines), Barberato, S (Barberato Filho, Silvio). (2010) Rocky Mountain spotted fever in Brazil. Rev Panam Salud Publica. 27(6) [http://www.scielosp.org.proxy1.cl.msu.edu/scielo.php?script=sci_arttext&pid=S1020-49892010000600008&lng=pt&nrm=iso&tlng=pt Full text]"
"Rickettsia rickettsii",12,"Peter J. Conlon MB, MRCPI, Gary W. Procop MD, Vance Fowler MD, Mohamed Ali Eloubeidi MD, Stephen R. Smith MD, MHS, Daniel J. Sexton. Predictors of prognosis and risk of acute renal failure in patients with Rocky Mountain spotted fever. 1996. The American Journal of Medicine. 101(6): 621-626 [http://www.sciencedirect.com.proxy1.cl.msu.edu/science/article/pii/S0002934396003324 Full text]"
"Rickettsia rickettsii",13,"Chapman, AS, Murphy, SM, Demma, LJ, Holman, RC, Curns, AT, McQuiston, JH, Krebs, JW, Swerdlow, DL. Rocky Mountain spotted fever in the United States, 1997-2002. (2006) VECTOR-BORNE AND ZOONOTIC DISEASES. 6(2): 170-178 [http://apps.webofknowledge.com.proxy1.cl.msu.edu/full_record.do?product=WOS&search_mode=GeneralSearch&qid=4&SID=1D1gPHggK1cOCGF5bMD&page=1&doc=1&cacheurlFromRightClick=no Abstract]"
"Rickettsia rickettsii",19,"Green, W. R., D. H. Walker, and B. G. Cain. 1978. Fatal viscerotropic Rocky Mountain spotted fever: report of a case diagnosed by immunofluorescence. Am. J. Med. 64:523-528."
"Rickettsia rickettsii",20,"Westerman, E. L. 1982. Rocky Mountain spotless fever. A dilemma for the clinician. Arch. Intern. Med. 142:1106-1107."
"Rickettsia rickettsii",21,"Wilson, L. B., and W. M. Chowning. 1904. Studies in Px'roplasinosis hoominis (""spotted fever"" or ""tick fever"" of the Rocky Mountains). J. Infect. Dis. 1:31-57."
"Rickettsia rickettsii",26,"Kaplowitz, L. G., J. J. Fischer, and P. F. Sparling. 1981. Rocky Mountain spotted fever: a clinical dilemma. Curr. Clin. Top. Infect. Dis. 2:89-108."
"Rickettsia rickettsii",28,"88. Miller, J. Q., and T. R. Price. 1972. The nervous system in
Rocky Mountain spotted fever. Neurology 22:561-566."
"Rickettsia rickettsii",29,"Helmick, C. G., K. W. Bernard, and L. J. D'Angelo. 1984. Rocky Mountain spotted fever: clinical, laboratory, and epidemiological features of 262 cases. J. Infect. Dis. 150:480-488."
"Rickettsia rickettsii",30,"Horney, L. F., and D. H. Walker. 1988. Meningoencephalitis as a major manifestation of Rocky Mountain spotted fever. South. Med. J. 81:915-918."
"Rickettsia rickettsii",32,"Miller, J. Q., and T. R. Price. 1972. The nervous system in Rocky Mountain spotted fever. Neurology 22:561-566."
"Rickettsia rickettsii",35,"Haynes, R. E., D. Y. Sanders, and H. G. Cramblett. 1970. Rocky Mountain spotted fever. Comments on recognition and management based on a study of 63 patients. Clin. Pediatr. 17:685-693."
"Rickettsia rickettsii",37,"Walker, D. H., and W. D. Mattern. 1979. Acute renal failure in Rocky Mountain spotted fever. Arch. Intern. Med. 139:443-448."
"Rickettsia rickettsii",40,"Bradford, W. D., B. P. Croker, and C. C. Tisher. 1979. Kidney lesions in Rocky Mountain spotted fever. A light-, immunofluorescence-, and electron-microscopic study. Am. J. Pathol. 97:381-390."
"Rickettsia rickettsii",42,"Adams, J. S., and D. H. Walker. 1981. The liver in Rocky Mountain spotted fever. Am. J. Clin. Pathol. 75:156-161."
"Rickettsia rickettsii",43,"Randall, M. R., and D. H. Walker. 1984. Gastrointestinal and pancreatic lesions and rickettsial infection in Rocky Mountain spotted fever. Arch. Pathol. Lab. Med. 108:963-967."
"Rickettsia rickettsii",46,"Davis, A. E., and W. D. Bradford. 1982. Abdominal pain resembling acute appendicitis in Rocky Mountain spotted fever. J. Am. Med. Assoc. 247:2811-2812."
"Rickettsia rickettsii",47,"Jiminez, J., W. J. Byrne, J. J. Seibert, and A. R. Euler. 1982. Gastrointestinal symptoms in Rocky Mountain spotted fever. Clin. Pediatr. 21:581 584."
"Rickettsia rickettsii",48,"Middleton, D. B. 1978. Rocky Mountain spotted fever: gastrointestinal and laboratory manifestations. South. Med. J. 71: 629-632."
"Rickettsia rickettsii",52,"Benson, M., and D. H. Walker. 1984. Rocky Mountain spotted fever in the differential diagnosis of the acute abdomen. Contemp. Surg. 24:79-83."
"Rickettsia rickettsii",53,"Walker, D. H. 1986. Gastroenterology of Rocky Mountain spotted fever. Pract. Gastroenterol. 10:25-39."
"Rickettsia rickettsii",54,"Walker, D. H., F. W. Henderson, and G. M. Hutchins. 1986. Rocky Mountain spotted fever: mimicry of appendicitis or acute surgical abdomen? Am. J. Dis. Child. 140:742-744."
"Rickettsia rickettsii",55,"Walker, D. H., H. R. Lesesne, V. A. Varma, and W. C. Thacker. 1985. Rocky Mountain spotted fever mimicking acute cholecystitis. Arch. Intern. Med. 145:2194-2196."
"Rickettsia rickettsii",56,"Weiss, E., and J. W. Moulder. 1984. The rickettsias and chlamydias, p. 687-739. In N. R. Kreig and J. G. Holt (ed.), Bergey's manual of systematic bacteriology, vol. 1. The Williams & Wilkins Co., Baltimore."
Rotavirus,1,http://en.wikipedia.org/wiki/Rotavirus
Rotavirus,2,"[http://www.cdc.gov/vaccines/pubs/surv-manual/chpt13-rotavirus.pdf CDC]"
Rotavirus,3,"Thea KÃ¸lsen Fischer, CeÂ´ cile Viboud, Umesh Parashar, Mark Malek, Claudia Steiner, Roger Glass,and Lone Simonsen. (2007) Hospitalizations and Deaths from Diarrhea and Rotavirus among Children 

=Burden of Disease=
Rotavirus was estimated to be the cause of ~60,000 hospitalizations annually when data were extrapolated to the US population.

====Duration of Infectiousness and disease====
====Symptomology====
Symptoms of infected individuals include fever, vomiting, diarrhea, and abdominal pain.  Loss of appetite and dehydration are also common, and especially harmful to infants and young children.

====Latency====
====Asymptomatic Rates====
====Excretion Rates (see Exposure) ====
====Immunity====

=Microbiology=
A genus of double-stranded RNA virus in the family Reoviridae

=Environmental Resistance=
Resistant to disinfection.

=Recommended Dose Response Model=
[[Rotavirus: Dose Response Models]]  Beta-Poisson, Î± is 2.53E-01, N50 is 6.17  [[File:Betapoisson_model.jpg|thumb|left|300px]]








===References===
 


[[Category:Agent Overview]][[Category:Virus]]"
"SARS coronavirus",1,"[http://emedicine.medscape.com/article/237755-overview#showall Medscape]"
"SARS coronavirus",2,"Update 49 - SARS case fatality ratio, incubation period, World Health Organization, 7 May 2003. URL Accessed 17 May 2008. [http://www.who.int/csr/sarsarchive/2003_05_07a/en/# Full text]"
"SARS coronavirus",4,"
Trivendi, M. Pinsky, M. (2011) âSevere Acute Respiratory Syndrome (SARS)""  Medscape Reference. Retrieved on 1-31-12 from http://emedicine.medscape.com/article/237755-overview#a0156"
"SARS coronavirus",5,"Center For Disease Control [http://www.cdc.gov/sars/about/fs-SARS.html Full Text]"
"SARS coronavirus",6,"[http://en.wikipedia.org/wiki/Severe_acute_respiratory_syndrome Wikipedia]"
Salmonella,1,"http://emedicine.medscape.com/article/785774-overview#showall Medscape"
Salmonella,2,"http://en.wikipedia.org/wiki/Salmonella Wikipedia"
Salmonella,3,"http://health.utah.gov/epi/fact_sheets/salmon.html Utah Department of Health"
Salmonella,4," CDC http://www.cdc.gov/salmonella/general/diagnosis.html "
Salmonella,5,"http://en.wikipedia.org/wiki/Salmonella Wikipedia"
"Salmonella Typhi: Dose Response Models",1,"Crump JA, Mintz ED, 2010 Global trends in typhoid and paratyphoid Fever. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 50(2), pp.241-246. [http://cid.oxfordjournals.org/content/50/2/241.full.pdf+html Full text]"
"Salmonella Typhi: Dose Response Models",2,"Miliotis MD, Bier J eds. (2003) International Handbook of Foodborne Pathogens, New York: M. Dekker."
"Salmonella Typhi: Dose Response Models",5,"Hornick RB, et al. (1966) Study of induced typhoid fever in man. I. Evaluation of vaccine effectiveness. Transactions of the Association of American Physicians. 79, pp.361-367."
"Salmonella Typhi: Dose Response Models",6,"Hornick RB, et al. (1970) Typhoid fever: pathogenesis and immunologic control. The New England Journal of Medicine. 283(13), pp.686-691. [http://www.nejm.org/doi/pdf/10.1056/NEJM197010012831406 Abstract]"
"Salmonella anatum: Dose Response Models",1,"
Chalker RB, Blaser MJ (1988) [http://www.jstor.org/stable/4454281 A review of human salmonellosis: III. Magnitude of Salmonella infection in the United States.] Reviews of Infectious Diseases 10(1): 111-124."
"Salmonella anatum: Dose Response Models",2,"Hartmann FA, West SE (1995) Antimicrobial susceptibility profiles of multidrug-resistant Salmonella anatum isolated from horses. Journal of Veterinary Diagnostic Investigation 7: 159-162."
"Salmonella anatum: Dose Response Models",3,"Krause G, Terzagian R, et al. (2001) Outbreak of Salmonella Serotype Anatum Infection Associated With Unpasteurized Orange Juice. Southern Medical Journal 94(12): 1168&hyhen;1172."
"Salmonella meleagridis: Dose Response Models",1,"McCullough NB, Eisele CW (1951) Experimental human salmonellosis. II. Immunity studies following experimental illness with Salmonella meleagridis and Salmonella anatum. Journal of immunology (Baltimore, Md. : 1950) 66(5): 595-608."
"Salmonella nontyphoid: Dose Response Models",1,"Meynell GG, Meynell EW (1958) [http://journals.cambridge.org/action/displayAbstract?fromPage=online&aid=4677220 The Growth of Micro-Organisms in vivo with Particular Reference to the Relation between Dose and Latent Period] Journal of Hygiene '''56'''(3): 323-346."
"Salmonella serotype newport: Dose Response Models",1,"
McCullough NB, Eisele CW (1951) Experimental Human Salmonellosis: III. Pathogenicity of Strains of Salmonella newport, Salmonella derby, and Salmonella bareilly Obtained from Spray-Dried Whole Egg. The Journal of Infectious Diseases 89(3): 209-213."
Sandbox,1,"
'''References'''


{{DRFit|filename=ADDFILENAMEHERE.xls|tablenum=ADDTABLENUMBERHERE|title=Goodness of fit and model selection|devE=2.99|devB=0.0156|delta=2.98|DFE=2|DFB=1|X2bPbetter=3.84|pbPbetter=0.0845|X2GOFe=5.99|pGOFe=0.224|X2GOFb=3.84|pGOFb=0.901|interpretation=Exponential is preferred to beta-Poisson; cannot reject good fit for exponential.}}

{{DRConfidenceBetaPoisson|filename=ADDFILENAMEHERE.xls|tablenum=ADDTABLENUMBERHERE|title=Optimized parameters for the beta-Poisson model, from 500 bootstrap iterations|MLEa=2.13E-01|p5a=1.26E-03|p25a=3.22E-02|p50a=3.22E-02|p950a=2.66E+02|p975a=3.62E+02|p995a=1.25E+03|MLEN=3.41E+07|p5N= 1.91E+06|p25N= 2.78E+06|p50N= 5.87E+06|p950N= 1.01E+14|p975N= 1.01E+14|p995N=9.22E+140}}

{{DRConfidenceExponential|filename=ADDFILENAMEHERE.xls|tablenum=ADDTABLENUMBERHERE|title=Optimized k parameter and N50 for the exponential model, from 500 bootstrap iterations|MLEk=2.13E-01|p5k=2.19E-09|p25k=2.19E-09|p50k=4.40E-09|p950k=4.03E-08|p975k=1.17E-07|p995k=2.50E-07|MLEN=3.41E+07|p5N=2.78E+06|p25N=5.92E+06|p50N=1.72E+07|p950N=1.58E+08|p975N=3.17E+08|p995N=3.17E+08}}



{{DRExperimentDataTable4|filename=ADDFILENAMEHERE.xls|tablenum=ADDTABLENUMBERHERE|title=TITLE|reference=ADDFULLREFERENCEHERE|pos=death|neg=not death|d1=100|p1=1|n1=3|t1=4|d2=1000|p2=3|n2=1|t2=4|d3=1E+04|p3=4|n3=0|t3=4|d4=1E+05|p4=4|n4=0|t4=4}}

{{DRFit|filename=ADDFILENAMEHERE.xls|tablenum=ADDTABLENUMBERHERE|title=Goodness of fit and model selection|devE=0.338|devB=0.142|delta=0.195|DFE=3|DFB=2|X2bPbetter=3.84|pbPbetter=0.658|X2GOFe=7.81|pGOFe=0.953|X2GOFb=5.99|pGOFb=0.931|interpretation=Exponential is preferred to beta-Poisson; cannot reject good fit for exponential.}}

{{DRConfidenceExponential|filename=ADDFILENAMEHERE.xls|tablenum=ADDTABLENUMBERHERE|title=Optimized k parameter and N50 for the exponential model, from 500 bootstrap iterations|MLEk=1.82E+00|p5k=3.62E-04|p25k=5.50E-04|p50k=6.22E-04|p950k=7.02E-03|p975k=7.02E-03|p995k=7.02E-03|MLEN=3.38E+02|p5N=9.87E+01|p25N=9.87E+01|p50N=9.87E+01|p950N=1.11E+03|p975N=1.26E+03|p995N=1.92E+03}}


The IHERA project brings together experts from India and the USA to integrate knowledge in the field of risk assessment, transmit this knowledge to the next generation of risk assessors, and identify knowledge gaps and research collaborations. The project aims to achieve the following three specific objectives:  (1) Develop a course curriculum on ecosystem and human health risk assessment with special reference to microbial contamination, (2) Train students, regulators, teachers, engineers, and researchers using developed course material at both I.I.T. Delhi and Drexel University, and (3) Identify research projects on human health risk issues. These objectives will be achieved through expertâs interactions at a curriculum development workshop, during collaborative preparation of course materials, and while team teaching during faculty exchange visits.



Although more than 50% of waterborne disease outbreaks are due to contaminated ground water, there is very little known about the persistency of these viruses (Yates et al., 1984). In order to determine the virus survival in ground water, Yates et al. (1984) compiled samples from 11 different sites around the United States of filtered and nonfiltered groundwater that were tested with three viruses: poliovirus 1, echovirus 1, and MS-2 coliphage. Over a span of 30 days, the samples were monitored to determine the level of infectivity that remained over time. The measurements were taken on predetermined days and the unit was CFU/ml.

To model the Yates et al. (1984) data, the information was inputted into R programming, Â© The R Foundation, to fit the 112 sets of data to the best fitting persistence model. This information is recorded in the table along with the associated k values, the T-90, the strain temperature, and the number of data points used in the set. The ""Best Fit"" column notes that some of the sets had similar BIC values for more than one persistence model. Further detail is given on the ID numberâs respective page. 


{| class=""wikitable""
|+ colspan=""15"" style=""text-align: left; font-weight: bold; color: black;"" | Summary of Best Fitting Models and Data on Yates Groundwater Samples
|-
| style=""text-align: center; font-weight: bold;"" | Agent
| style=""text-align: center; font-weight: bold;"" | ID
| style=""text-align: center; font-weight: bold;"" | Best Fit Model
| style=""text-align: center; font-weight: bold;"" | k-value 1
| style=""text-align: center; font-weight: bold;"" | k-value 2
| style=""text-align: center; font-weight: bold;"" | k-value 3
| style=""text-align: center; font-weight: bold;"" | Sole Best Fit?
| style=""text-align: center; font-weight: bold;"" | T-90
| style=""text-align: center; font-weight: bold;"" | Matrix
| style=""text-align: center; font-weight: bold;"" | Strain
| style=""text-align: center; font-weight: bold;"" | Temp *C
| style=""text-align: center; font-weight: bold;"" | # of data points
| style=""text-align: center; font-weight: bold;"" | Measurement units
| style=""text-align: center; font-weight: bold;"" | Other Factors
| style=""text-align: center; font-weight: bold;"" | Region
|-
| style=""text-align: center;"" | Echovirus
| style=""text-align: center;"" | 1
| style=""text-align: center;"" | Gompertz 3
| style=""text-align: center;"" | -2.309
| style=""text-align: center;"" | 0.299
| style=""text-align: center;"" | 2.395
| style=""text-align: center;"" | Yes
| style=""text-align: center;"" | 5.739
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 13
| style=""text-align: center;"" | 9
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Texas 1
|-
| style=""text-align: center;"" | Echovirus
| style=""text-align: center;"" | 2
| style=""text-align: center;"" | Juneja and Marks (2)
| style=""text-align: center;"" | -2.457
| style=""text-align: center;"" | 2.458
| style=""text-align: center;"" | 
| style=""text-align: center;"" | Yes
| style=""text-align: center;"" | 6.642
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 17
| style=""text-align: center;"" | 11
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | California 2
|-
| style=""text-align: center;"" | Echovirus
| style=""text-align: center;"" | 3
| style=""text-align: center;"" | Double exponential
| style=""text-align: center;"" | 0.906
| style=""text-align: center;"" | 0.115
| style=""text-align: center;"" | 0.931
| style=""text-align: center;"" | Yes
| style=""text-align: center;"" | 3.181
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 12
| style=""text-align: center;"" | 13
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Wisconsin
|-
| style=""text-align: center;"" | MS-2 Phage
| style=""text-align: center;"" | 4
| style=""text-align: center;"" | Double exponential
| style=""text-align: center;"" | -3.337
| style=""text-align: center;"" | 1.675
| style=""text-align: center;"" | 0.000
| style=""text-align: center;"" | Yes
| style=""text-align: center;"" | 1.374
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 6
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | MS-2 Phage
| style=""text-align: center;"" | 5
| style=""text-align: center;"" | Juneja and Marks (1)
| style=""text-align: center;"" | 0.841
| style=""text-align: center;"" | 0.070
| style=""text-align: center;"" | 
| style=""text-align: center;"" | Yes
| style=""text-align: center;"" | 0.297
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | MS-2 Phage
| style=""text-align: center;"" | 6
| style=""text-align: center;"" | Juneja and Marks (1)
| style=""text-align: center;"" | 0.401
| style=""text-align: center;"" | 0.111
| style=""text-align: center;"" | 
| style=""text-align: center;"" | Yes
| style=""text-align: center;"" | 1.220
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | MS-2 Phage
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | Gamma
| style=""text-align: center;"" | 2.336
| style=""text-align: center;"" | 0.145
| style=""text-align: center;"" | 
| style=""text-align: center;"" | Yes
| style=""text-align: center;"" | 1.002
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | MS-2 Phage
| style=""text-align: center;"" | 8
| style=""text-align: center;"" | Juneja and Marks (1)
| style=""text-align: center;"" | 0.471
| style=""text-align: center;"" | 0.099
| style=""text-align: center;"" | 
| style=""text-align: center;"" | Yes
| style=""text-align: center;"" | 0.896
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 9
| style=""text-align: center;"" | Juneja and Marks (2)
| style=""text-align: center;"" | -0.249
| style=""text-align: center;"" | 1.688
| style=""text-align: center;"" | 
| style=""text-align: center;"" | Yes
| style=""text-align: center;"" | 4.260
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 13
| style=""text-align: center;"" | 11
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | Texas 2
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 10
| style=""text-align: center;"" | Juneja and Marks (2)
| style=""text-align: center;"" | -1.433
| style=""text-align: center;"" | 2.307
| style=""text-align: center;"" | 
| style=""text-align: center;"" | Yes
| style=""text-align: center;"" | 4.823
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 17
| style=""text-align: center;"" | 11
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | California 2
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 11
| style=""text-align: center;"" | Juneja and Marks (1)
| style=""text-align: center;"" | 0.074
| style=""text-align: center;"" | 0.005
| style=""text-align: center;"" | 
| style=""text-align: center;"" | Yes
| style=""text-align: center;"" | 0.000
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 12
| style=""text-align: center;"" | Exponential Damped
| style=""text-align: center;"" | 2.510
| style=""text-align: center;"" | 0.152
| style=""text-align: center;"" | 
| style=""text-align: center;"" | Yes
| style=""text-align: center;"" | 1.082
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 13
| style=""text-align: center;"" | Juneja and Marks (2)
| style=""text-align: center;"" | 4.842
| style=""text-align: center;"" | 1.004
| style=""text-align: center;"" | 
| style=""text-align: center;"" | Yes
| style=""text-align: center;"" | 0.072
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 14
| style=""text-align: center;"" | Juneja and Marks (2)
| style=""text-align: center;"" | 5.009
| style=""text-align: center;"" | 1.093
| style=""text-align: center;"" | 
| style=""text-align: center;"" | Yes
| style=""text-align: center;"" | 0.076
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 15
| style=""text-align: center;"" | Double exponential
| style=""text-align: center;"" | 2.855
| style=""text-align: center;"" | 0.391
| style=""text-align: center;"" | 0.970
| style=""text-align: center;"" | Yes
| style=""text-align: center;"" | 0.880
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 16
| style=""text-align: center;"" | Juneja and Marks (2)
| style=""text-align: center;"" | 4.831
| style=""text-align: center;"" | 1.504
| style=""text-align: center;"" | 
| style=""text-align: center;"" | Yes
| style=""text-align: center;"" | 0.174
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 17
| style=""text-align: center;"" | Weibull
| style=""text-align: center;"" | 0.856
| style=""text-align: center;"" | 0.467
| style=""text-align: center;"" | 
| style=""text-align: center;"" | Yes
| style=""text-align: center;"" | 0.856
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 18
| style=""text-align: center;"" | Juneja and Marks (2)
| style=""text-align: center;"" | 3.638
| style=""text-align: center;"" | 1.512
| style=""text-align: center;"" | 
| style=""text-align: center;"" | Yes
| style=""text-align: center;"" | 0.386
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 19
| style=""text-align: center;"" | Juneja and Marks (1)
| style=""text-align: center;"" | 0.304
| style=""text-align: center;"" | 0.032
| style=""text-align: center;"" | 
| style=""text-align: center;"" | Yes
| style=""text-align: center;"" | 0.128
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 20
| style=""text-align: center;"" | Juneja and Marks (2)
| style=""text-align: center;"" | 4.725
| style=""text-align: center;"" | 0.821
| style=""text-align: center;"" | 
| style=""text-align: center;"" | Yes
| style=""text-align: center;"" | 0.046
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | Echovirus
| style=""text-align: center;"" | 21
| style=""text-align: center;"" | Double exponential
| style=""text-align: center;"" | 0.225
| style=""text-align: center;"" | 3.555
| style=""text-align: center;"" | 0.461
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 7.136
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 12
| style=""text-align: center;"" | 9
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | North Carolina 1
|-
| style=""text-align: center;"" | Echovirus
| style=""text-align: center;"" | 22
| style=""text-align: center;"" | Juneja and Marks (1)
| style=""text-align: center;"" | 0.413
| style=""text-align: center;"" | 0.477
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 4.287
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 12
| style=""text-align: center;"" | 9
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | North Carolina 1
|-
| style=""text-align: center;"" | Echovirus
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | Linear
| style=""text-align: center;"" | 0.099
| style=""text-align: center;"" | 1.280
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 5.507
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 12
| style=""text-align: center;"" | 9
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | North Carolina 2
|-
| style=""text-align: center;"" | Echovirus
| style=""text-align: center;"" | 24
| style=""text-align: center;"" | Exponential
| style=""text-align: center;"" | 0.416
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 5.384
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 12
| style=""text-align: center;"" | 9
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | North Carolina 2
|-
| style=""text-align: center;"" | Echovirus
| style=""text-align: center;"" | 25
| style=""text-align: center;"" | Exponential
| style=""text-align: center;"" | 1.447
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 1.599
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 6
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | Univ. of Arizona
|-
| style=""text-align: center;"" | Echovirus
| style=""text-align: center;"" | 26
| style=""text-align: center;"" | Juneja and Marks (1)
| style=""text-align: center;"" | 1.367
| style=""text-align: center;"" | 0.390
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 1.221
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 6
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Univ. of Arizona
|-
| style=""text-align: center;"" | Echovirus
| style=""text-align: center;"" | 27
| style=""text-align: center;"" | Juneja and Marks (2)
| style=""text-align: center;"" | -2.057
| style=""text-align: center;"" | 1.445
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 19.098
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 12
| style=""text-align: center;"" | 10
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | New York 1
|-
| style=""text-align: center;"" | Echovirus
| style=""text-align: center;"" | 28
| style=""text-align: center;"" | Juneja and Marks (2)
| style=""text-align: center;"" | -3.491
| style=""text-align: center;"" | 1.872
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 20.962
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 12
| style=""text-align: center;"" | 10
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | New York 1
|-
| style=""text-align: center;"" | Echovirus
| style=""text-align: center;"" | 29
| style=""text-align: center;"" | Juneja and Marks (1)
| style=""text-align: center;"" | 0.015
| style=""text-align: center;"" | 0.086
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 24.684
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 12
| style=""text-align: center;"" | 10
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | New York 2
|-
| style=""text-align: center;"" | Echovirus
| style=""text-align: center;"" | 30
| style=""text-align: center;"" | Juneja and Marks (1)
| style=""text-align: center;"" | 0.089
| style=""text-align: center;"" | 0.342
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 14.639
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 12
| style=""text-align: center;"" | 10
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | New York 2
|-
| style=""text-align: center;"" | Echovirus
| style=""text-align: center;"" | 31
| style=""text-align: center;"" | Juneja and Marks (2)
| style=""text-align: center;"" | -1.560
| style=""text-align: center;"" | 1.859
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 8.740
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 13
| style=""text-align: center;"" | 11
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | Texas 1
|-
| style=""text-align: center;"" | Echovirus
| style=""text-align: center;"" | 32
| style=""text-align: center;"" | Juneja and Marks (2)
| style=""text-align: center;"" | -3.581
| style=""text-align: center;"" | 2.849
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 7.885
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 13
| style=""text-align: center;"" | 10
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | Texas 2
|-
| style=""text-align: center;"" | Echovirus
| style=""text-align: center;"" | 33
| style=""text-align: center;"" | Juneja and Marks (2)
| style=""text-align: center;"" | -1.816
| style=""text-align: center;"" | 1.933
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 8.329
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 13
| style=""text-align: center;"" | 10
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Texas 2
|-
| style=""text-align: center;"" | Echovirus
| style=""text-align: center;"" | 34
| style=""text-align: center;"" | Juneja and Marks (2)
| style=""text-align: center;"" | -1.365
| style=""text-align: center;"" | 1.572
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 9.890
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 18
| style=""text-align: center;"" | 11
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | California 1
|-
| style=""text-align: center;"" | Echovirus
| style=""text-align: center;"" | 35
| style=""text-align: center;"" | Juneja and Marks (2)
| style=""text-align: center;"" | -4.833
| style=""text-align: center;"" | 3.611
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 7.262
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 18
| style=""text-align: center;"" | 8
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | California 1
|-
| style=""text-align: center;"" | Echovirus
| style=""text-align: center;"" | 36
| style=""text-align: center;"" | Juneja and Marks (2)
| style=""text-align: center;"" | -3.330
| style=""text-align: center;"" | 2.632
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 8.753
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 17
| style=""text-align: center;"" | 9
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | California 2
|-
| style=""text-align: center;"" | Echovirus
| style=""text-align: center;"" | 37
| style=""text-align: center;"" | Juneja and Marks (2)
| style=""text-align: center;"" | -2.153
| style=""text-align: center;"" | 3.599
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 3.246
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 9
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | MS-2 Phage
| style=""text-align: center;"" | 38
| style=""text-align: center;"" | Weibull
| style=""text-align: center;"" | 0.449
| style=""text-align: center;"" | 0.767
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 0.425
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 4
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | MS-2 Phage
| style=""text-align: center;"" | 39
| style=""text-align: center;"" | Juneja and Marks (1)
| style=""text-align: center;"" | 0.950
| style=""text-align: center;"" | 0.014
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 0.268
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 6
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | MS-2 Phage
| style=""text-align: center;"" | 40
| style=""text-align: center;"" | Exponential Damped
| style=""text-align: center;"" | 5.025
| style=""text-align: center;"" | 0.125
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 0.477
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 4
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | MS-2 Phage
| style=""text-align: center;"" | 41
| style=""text-align: center;"" | Juneja and Marks (1)
| style=""text-align: center;"" | 1.223
| style=""text-align: center;"" | 0.071
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 0.236
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 6
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | MS-2 Phage
| style=""text-align: center;"" | 42
| style=""text-align: center;"" | Juneja and Marks (1)
| style=""text-align: center;"" | 0.429
| style=""text-align: center;"" | 0.064
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 0.775
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 8
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | MS-2 Phage
| style=""text-align: center;"" | 43
| style=""text-align: center;"" | Double exponential
| style=""text-align: center;"" | 0.428
| style=""text-align: center;"" | 16.044
| style=""text-align: center;"" | 0.149
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 1.171
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 8
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | MS-2 Phage
| style=""text-align: center;"" | 44
| style=""text-align: center;"" | Juneja and Marks (1)
| style=""text-align: center;"" | 0.911
| style=""text-align: center;"" | 0.416
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 1.851
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | MS-2 Phage
| style=""text-align: center;"" | 45
| style=""text-align: center;"" | Weibull
| style=""text-align: center;"" | 1.131
| style=""text-align: center;"" | 0.385
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 1.112
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | MS-2 Phage
| style=""text-align: center;"" | 46
| style=""text-align: center;"" | Juneja and Marks (1)
| style=""text-align: center;"" | 0.492
| style=""text-align: center;"" | 0.082
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 0.683
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | MS-2 Phage
| style=""text-align: center;"" | 47
| style=""text-align: center;"" | Juneja and Marks (1)
| style=""text-align: center;"" | 0.435
| style=""text-align: center;"" | 0.152
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 1.599
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 8
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | MS-2 Phage
| style=""text-align: center;"" | 48
| style=""text-align: center;"" | Double exponential
| style=""text-align: center;"" | 0.573
| style=""text-align: center;"" | 16.427
| style=""text-align: center;"" | 0.275
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 1.788
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | MS-2 Phage
| style=""text-align: center;"" | 49
| style=""text-align: center;"" | Weibull
| style=""text-align: center;"" | 1.199
| style=""text-align: center;"" | 0.482
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 1.158
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 8
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | MS-2 Phage
| style=""text-align: center;"" | 50
| style=""text-align: center;"" | Juneja and Marks (1)
| style=""text-align: center;"" | 0.481
| style=""text-align: center;"" | 0.200
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 1.876
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | MS-2 Phage
| style=""text-align: center;"" | 51
| style=""text-align: center;"" | Juneja and Marks (1)
| style=""text-align: center;"" | 0.406
| style=""text-align: center;"" | 0.070
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 0.867
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 8
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | MS-2 Phage
| style=""text-align: center;"" | 52
| style=""text-align: center;"" | Juneja and Marks (1)
| style=""text-align: center;"" | 0.566
| style=""text-align: center;"" | 0.433
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 2.780
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | MS-2 Phage
| style=""text-align: center;"" | 53
| style=""text-align: center;"" | Gamma
| style=""text-align: center;"" | 0.968
| style=""text-align: center;"" | 0.280
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 1.081
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 6
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | MS-2 Phage
| style=""text-align: center;"" | 54
| style=""text-align: center;"" | Weibull
| style=""text-align: center;"" | 2.440
| style=""text-align: center;"" | 0.448
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 2.440
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 8
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | MS-2 Phage
| style=""text-align: center;"" | 55
| style=""text-align: center;"" | Juneja and Marks (1)
| style=""text-align: center;"" | 0.813
| style=""text-align: center;"" | 0.463
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 2.053
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | MS-2 Phage
| style=""text-align: center;"" | 56
| style=""text-align: center;"" | Exponential
| style=""text-align: center;"" | 2.026
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 0.988
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 5
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | MS-2 Phage
| style=""text-align: center;"" | 57
| style=""text-align: center;"" | Double exponential
| style=""text-align: center;"" | -0.691
| style=""text-align: center;"" | 2.015
| style=""text-align: center;"" | 0.000
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 1.002
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 6
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | MS-2 Phage
| style=""text-align: center;"" | 58
| style=""text-align: center;"" | Juneja and Marks (1)
| style=""text-align: center;"" | 0.511
| style=""text-align: center;"" | 0.087
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 0.869
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | MS-2 Phage
| style=""text-align: center;"" | 59
| style=""text-align: center;"" | Juneja and Marks (1)
| style=""text-align: center;"" | 0.468
| style=""text-align: center;"" | 0.120
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 1.318
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 8
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | MS-2 Phage
| style=""text-align: center;"" | 60
| style=""text-align: center;"" | Juneja and Marks (1)
| style=""text-align: center;"" | 0.638
| style=""text-align: center;"" | 0.189
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 1.504
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | MS-2 Phage
| style=""text-align: center;"" | 61
| style=""text-align: center;"" | Gamma
| style=""text-align: center;"" | 2.012
| style=""text-align: center;"" | 0.108
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 0.635
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | MS-2 Phage
| style=""text-align: center;"" | 62
| style=""text-align: center;"" | Juneja and Marks (1)
| style=""text-align: center;"" | 0.664
| style=""text-align: center;"" | 0.337
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 1.984
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | MS-2 Phage
| style=""text-align: center;"" | 63
| style=""text-align: center;"" | Exponential Damped
| style=""text-align: center;"" | 1.505
| style=""text-align: center;"" | -0.075
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 1.352
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 5
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | MS-2 Phage
| style=""text-align: center;"" | 64
| style=""text-align: center;"" | Juneja and Marks (1)
| style=""text-align: center;"" | 0.776
| style=""text-align: center;"" | 0.085
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 0.420
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | MS-2 Phage
| style=""text-align: center;"" | 65
| style=""text-align: center;"" | Gamma
| style=""text-align: center;"" | 0.954
| style=""text-align: center;"" | 0.132
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 0.490
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 6
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | MS-2 Phage
| style=""text-align: center;"" | 66
| style=""text-align: center;"" | Juneja and Marks (1)
| style=""text-align: center;"" | 0.940
| style=""text-align: center;"" | 0.258
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 1.273
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | MS-2 Phage
| style=""text-align: center;"" | 67
| style=""text-align: center;"" | Exponential
| style=""text-align: center;"" | 1.601
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 1.280
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 6
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | MS-2 Phage
| style=""text-align: center;"" | 68
| style=""text-align: center;"" | Gamma
| style=""text-align: center;"" | 2.040
| style=""text-align: center;"" | 0.156
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 0.880
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | MS-2 Phage
| style=""text-align: center;"" | 69
| style=""text-align: center;"" | Juneja and Marks (1)
| style=""text-align: center;"" | 0.891
| style=""text-align: center;"" | 0.215
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 1.216
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | MS-2 Phage
| style=""text-align: center;"" | 70
| style=""text-align: center;"" | Logistic
| style=""text-align: center;"" | 2.676
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 1.026
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 5
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 71
| style=""text-align: center;"" | Juneja and Marks (1)
| style=""text-align: center;"" | 0.386
| style=""text-align: center;"" | 0.177
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 2.047
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 12
| style=""text-align: center;"" | 9
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | North Carolina 1
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 72
| style=""text-align: center;"" | Juneja and Marks (1)
| style=""text-align: center;"" | 0.301
| style=""text-align: center;"" | 0.077
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 1.152
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 12
| style=""text-align: center;"" | 9
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | North Carolina 1
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 73
| style=""text-align: center;"" | Linear
| style=""text-align: center;"" | 0.163
| style=""text-align: center;"" | 0.852
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 3.609
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 12
| style=""text-align: center;"" | 9
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | North Carolina 2
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 74
| style=""text-align: center;"" | Double exponential
| style=""text-align: center;"" | 0.243
| style=""text-align: center;"" | 14.744
| style=""text-align: center;"" | 0.320
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 5.359
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 12
| style=""text-align: center;"" | 9
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | North Carolina 2
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 75
| style=""text-align: center;"" | Gamma
| style=""text-align: center;"" | 0.528
| style=""text-align: center;"" | 2.513
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 2.407
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 6
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | Univ. of Arizona
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 76
| style=""text-align: center;"" | Gamma
| style=""text-align: center;"" | 0.488
| style=""text-align: center;"" | 2.477
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 2.247
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 6
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Univ. of Arizona
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 77
| style=""text-align: center;"" | Exponential Damped
| style=""text-align: center;"" | 0.139
| style=""text-align: center;"" | 0.034
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 45.118
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 12
| style=""text-align: center;"" | 10
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | New York 1
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 78
| style=""text-align: center;"" | Juneja and Marks (2)
| style=""text-align: center;"" | -0.949
| style=""text-align: center;"" | 0.922
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 27.711
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 12
| style=""text-align: center;"" | 10
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | New York 1
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 79
| style=""text-align: center;"" | Gompertz 3
| style=""text-align: center;"" | -1.034
| style=""text-align: center;"" | 0.220
| style=""text-align: center;"" | 2.490
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 11.749
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 12
| style=""text-align: center;"" | 10
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | New York 2
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 80
| style=""text-align: center;"" | Double exponential
| style=""text-align: center;"" | 0.009
| style=""text-align: center;"" | 0.647
| style=""text-align: center;"" | 0.046
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 5.124
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 12
| style=""text-align: center;"" | 10
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | New York 2
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 81
| style=""text-align: center;"" | Double exponential
| style=""text-align: center;"" | 0.112
| style=""text-align: center;"" | 0.636
| style=""text-align: center;"" | 0.185
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 6.993
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 13
| style=""text-align: center;"" | 11
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | Texas 1
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 82
| style=""text-align: center;"" | Juneja and Marks (1)
| style=""text-align: center;"" | 0.039
| style=""text-align: center;"" | 0.088
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 9.688
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 13
| style=""text-align: center;"" | 11
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Texas 1
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 83
| style=""text-align: center;"" | Juneja and Marks (2)
| style=""text-align: center;"" | -0.518
| style=""text-align: center;"" | 2.322
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 3.147
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 13
| style=""text-align: center;"" | 8
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Texas 2
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 84
| style=""text-align: center;"" | Double exponential
| style=""text-align: center;"" | 0.068
| style=""text-align: center;"" | 0.823
| style=""text-align: center;"" | 0.038
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 3.552
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 18
| style=""text-align: center;"" | 10
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | California 1
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 85
| style=""text-align: center;"" | Weibull
| style=""text-align: center;"" | 2.480
| style=""text-align: center;"" | 0.604
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 2.572
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 18
| style=""text-align: center;"" | 8
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | California 1
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 86
| style=""text-align: center;"" | Exponential Damped
| style=""text-align: center;"" | 0.627
| style=""text-align: center;"" | 0.051
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 4.653
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 17
| style=""text-align: center;"" | 10
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | California 2
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 87
| style=""text-align: center;"" | Juneja and Marks (2)
| style=""text-align: center;"" | 2.204
| style=""text-align: center;"" | 2.338
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 0.970
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 88
| style=""text-align: center;"" | Juneja and Marks (2)
| style=""text-align: center;"" | 3.720
| style=""text-align: center;"" | 1.901
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 0.151
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 89
| style=""text-align: center;"" | Weibull
| style=""text-align: center;"" | 0.771
| style=""text-align: center;"" | 0.509
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 0.528
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 90
| style=""text-align: center;"" | Gamma
| style=""text-align: center;"" | 7.361
| style=""text-align: center;"" | 0.015
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 0.106
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 91
| style=""text-align: center;"" | Juneja and Marks (2)
| style=""text-align: center;"" | 2.177
| style=""text-align: center;"" | 1.791
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 0.702
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 92
| style=""text-align: center;"" | Juneja and Marks (2)
| style=""text-align: center;"" | 4.742
| style=""text-align: center;"" | 1.106
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 0.033
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 93
| style=""text-align: center;"" | Juneja and Marks (1)
| style=""text-align: center;"" | 0.282
| style=""text-align: center;"" | 0.019
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 0.114
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 94
| style=""text-align: center;"" | Juneja and Marks (2)
| style=""text-align: center;"" | 3.868
| style=""text-align: center;"" | 1.062
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 0.089
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 95
| style=""text-align: center;"" | Juneja and Marks (1)
| style=""text-align: center;"" | 0.467
| style=""text-align: center;"" | 0.022
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 0.157
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 96
| style=""text-align: center;"" | Juneja and Marks (2)
| style=""text-align: center;"" | 5.341
| style=""text-align: center;"" | 1.186
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 0.024
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 97
| style=""text-align: center;"" | Juneja and Marks (1)
| style=""text-align: center;"" | 1.390
| style=""text-align: center;"" | 0.298
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 0.871
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 5
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 98
| style=""text-align: center;"" | Gamma
| style=""text-align: center;"" | 2.501
| style=""text-align: center;"" | 0.036
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 0.172
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 99
| style=""text-align: center;"" | Juneja and Marks (2)
| style=""text-align: center;"" | 2.654
| style=""text-align: center;"" | 1.144
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 0.426
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 100
| style=""text-align: center;"" | Juneja and Marks (2)
| style=""text-align: center;"" | 2.740
| style=""text-align: center;"" | 1.238
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 0.386
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 101
| style=""text-align: center;"" | Weibull
| style=""text-align: center;"" | 0.003
| style=""text-align: center;"" | 0.132
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 0.012
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 102
| style=""text-align: center;"" | Juneja and Marks (1)
| style=""text-align: center;"" | 1.008
| style=""text-align: center;"" | 0.030
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 0.152
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 5
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 103
| style=""text-align: center;"" | Juneja and Marks (1)
| style=""text-align: center;"" | 0.378
| style=""text-align: center;"" | 0.028
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 0.194
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 104
| style=""text-align: center;"" | Juneja and Marks (2)
| style=""text-align: center;"" | 3.343
| style=""text-align: center;"" | 1.894
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 0.189
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 105
| style=""text-align: center;"" | Juneja and Marks (2)
| style=""text-align: center;"" | 2.392
| style=""text-align: center;"" | 2.079
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 0.659
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 106
| style=""text-align: center;"" | Gamma
| style=""text-align: center;"" | 4.486
| style=""text-align: center;"" | 0.014
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 0.118
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 107
| style=""text-align: center;"" | Double exponential
| style=""text-align: center;"" | 3.192
| style=""text-align: center;"" | 0.439
| style=""text-align: center;"" | 0.951
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 0.659
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 108
| style=""text-align: center;"" | Juneja and Marks (2)
| style=""text-align: center;"" | 3.585
| style=""text-align: center;"" | 1.664
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 0.147
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 109
| style=""text-align: center;"" | Gamma
| style=""text-align: center;"" | 11.269
| style=""text-align: center;"" | 0.004
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 0.020
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 110
| style=""text-align: center;"" | Juneja and Marks (1)
| style=""text-align: center;"" | 0.450
| style=""text-align: center;"" | 0.023
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 0.200
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Filtered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 111
| style=""text-align: center;"" | Exponential
| style=""text-align: center;"" | 0.853
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 2.556
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 23
| style=""text-align: center;"" | 7
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Arizona
|-
| style=""text-align: center;"" | Poliovirus
| style=""text-align: center;"" | 112
| style=""text-align: center;"" | Gamma
| style=""text-align: center;"" | 10.242
| style=""text-align: center;"" | 0.243
| style=""text-align: center;"" | 
| style=""text-align: center;"" | No
| style=""text-align: center;"" | 7.081
| style=""text-align: center;"" | Ground Water
| style=""text-align: center;"" | 
| style=""text-align: center;"" | 12
| style=""text-align: center;"" | 13
| style=""text-align: center;"" | CFU/ml
| style=""text-align: center;"" | Nonfiltered
| style=""text-align: center;"" | Wisconsin
|}"
"Shigella: Dose Response Models",1,"Kaper JB, Nataro JP, & Mobley HL, (2004) [http://www.nature.com/nrmicro/journal/v2/n2/pdf/nrmicro818.pdf Pathogenic Escherichia coli.] Nature Reviews. Microbiology, 2(2), pp.123-140. "
"Shigella: Dose Response Models",2,"Kotloff KL, et al., (1999) [http://www.who.int/bulletin/archives/77%288%29651.pdf Global burden of Shigella infections: implications for vaccine development and implementation of control strategies.] Bulletin of the World Health Organization, 77(8), pp.651-666."
"Shigella: Dose Response Models",3,"Heymann DL, (2004) Control of Communicable Diseases Manual 18th ed., American Public Health Association."
"Shigella: Dose Response Models",5,"Niyogi SK, (2005) [http://www.ncbi.nlm.nih.gov/pubmed/15880088/ Shigellosis.] ''Journal of Microbiology (Seoul, Korea)'', 43(2), pp.133-143. "
"Shigella: Dose Response Models",9,"American Water Works Association, (1999) Waterborne pathogens: manual of water supply practices, Denver, CO: American Water Works Association."
"Shigella: Dose Response Models",13,"Crockett CS, et al., (1996) [http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T7K-3W3NF3S-7&_user=1111158&_coverDate=06%2F30%2F1996&_rdoc=1&_fmt=high&_orig=gateway&_origin=gateway&_sort=d&_docanchor=&view=c&_searchStrId=1722657331&_rerunOrigin=scholar.google&_acct=C000051676&_version=1&_urlVersion=0&_userid=1111158&md5=bff3817b1ad23283b324c4af28734d6e&searchtype=a Prevalence of shigellosis in the U.S.: consistency with dose-response information.] International Journal of Food Microbiology, 30(1-2), pp.87-99. "
"Shigella: Dose Response Models",14,"Haas CN, Rose JB, Gerba CP, (1999) Quantitative Microbial Risk Assessment, John Wiley & Sons, Inc."
"Shigella: Dose Response Models",16,"Powell MR, (2000) [http://www.springerlink.com/content/k3t3768n75w16246/fulltext.pdf Dose-response envelope for Escherichia coli O157:H7.] Quantitative Microbiology, 2, pp.141-163."
"Shigella: Dose Response Models",17,"DuPont HL, et al., (1969) [http://www.jstor.org/stable/30102317 The response of man to virulent Shigella flexneri 2a.] The Journal of Infectious Diseases, 119(3), pp.296-299."
"Shigella: Dose Response Models",18,"DuPont HL, et al. (1972) [http://jid.oxfordjournals.org/content/125/1/5.short Immunity in shigellosis. I. Response of man to attenuated strains of Shigella.] ''The Journal of Infectious Diseases'', 125(1), pp.5-16."
"Shigella: Dose Response Models",22,"DuPont HL, et al., (1989) [http://www.jstor.org/stable/30137443 Inoculum size in shigellosis and implications for expected mode of transmission.] The Journal of Infectious Diseases, 159(6), pp.1126-1128. "
"Shigella: Dose Response Models",23,"DuPont HL, et al., (1972a) [http://jid.oxfordjournals.org/content/125/1/5.short Immunity in shigellosis. I. Response of man to attenuated strains of Shigella.] ''The Journal of Infectious Diseases'', 125(1), pp.5-11."
"Shigella: Dose Response Models",25,"Kotloff KL, et al., (1995) [http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6TD4-3Y44SK2-11-5&_cdi=5188&_user=1111158&_pii=0264410X95001027&_origin=gateway&_coverDate=12%2F31%2F1995&_sk=999869983&view=c&wchp=dGLzVtz-zSkzk&md5=d83bc555ae4859d05782081cdc6f5da2&ie=/sdarticle.pdf A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity.] Vaccine, 13(16), pp.1488-1494."
"Shigella sp.",1,"Sur, Dipika et al. âShigellosisâ¯: Challenges & Management Issues.â The Indian Journal of Medical Research 120.5 (2004): 454â462."
"Shigella sp.",5," CDC http://www.cdc.gov/nczved/divisions/dfbmd/diseases/shigellosis/#diagnose> "
"Shigella sp.",6," http://site.ebrary.com.proxy1.cl.msu.edu/lib/michstate/docDetail.action?docID=10422483> "
"Social Science of Risk",1,"Morgan MG, Fischhoff B, Bostrom A and Atman CJ (2002) Risk communication: a mental models approach. Cambridgeâ¯; New York: Cambridge University Press"
"Social Science of Risk",2,"Fischhoff B (1995) Risk perception and communication unplugged: twenty years of process. Risk analysis: an official publication of the Society for Risk Analysis. 15 (2), 137â145."
"Social Science of Risk",3,"Slovic P, Fischhoff B and Lichtenstein S (1980) Understanding Perceived Risk. In: Schwing R and Albers W (eds) Societal risk assessment: how safe is safe enough? New York: Plenum Press."
"Social Science of Risk",4,"Slovic P, Finucane ML, Peters E and MacGregor DG (2004) Risk as analysis and risk as feelings: some thoughts about affect, reason, risk, and rationality. Risk analysis: an official publication of the Society for Risk Analysis 24(2): 311â322."
"Social Science of Risk",6,"[http://www.cdc.gov/owcd/eet/Cost/fixed/3.html CDC Cost of Illness]"
"Social Science of Risk",7,"[http://www.epa.gov/oppt/coi/pubs/I_1.pdf EPA Cost of Illness Handbook]"
"Social Science of Risk",9,"Viscusi WK and Aldy JE (2003) The value of a statistical life: A critical review of market estimates throughout the world. Journal of Risk and Uncertainty. 27 (1), 5â76."
"Social Science of Risk",10,"Gold MR, Stevenson D and Fryback DG (2002) HALYS and QALYS and DALYS, Oh My: similarities and differences in summary measures of population Health. Annual review of public health. 23, 115â134."
"Social Science of Risk",12,"Murray CJL and Lopez AD eds. (1996) The Global Burden of Disease: a Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Cambridge, Mass.: Published by the Harvard School of Public Health on behalf of the World Health Organization and the World Bank"
"Social Science of Risk",14,"Kaplan RM and Anderson JP (1988) A general health policy model: update and applications. Health services research. 23 (2), 203â235.
"
"Social Science of Risk",15,"Horsman J, Furlong W, Feeny D and Torrance G (2003) The Health Utilities Index (HUIÂ®): concepts, measurement properties and applications. Health and Quality of Life Outcomes. 1, 54."
"Social Science of Risk",18,"Shepard CW, Soriano-Gabarro M, Zell ER, Hayslett J, Lukacs S, Goldstein S, Factor S, Jones J, Ridzon R, Williams I and Rosenstein N (2002) Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence. Emerging infectious diseases. 8 (10), 1124â1132."
"Social Science of Risk",19,"World Health Organization (2010) Treatment of tuberculosis guidelines (4th edition). Geneva, Switzerland"
"Social Science of Risk",20,"World Health Organization (2003) Adherence to long-term therapies: evidence for action. Geneva, Switzerland Available at: http://www.who.int/chp/knowledge/publications/adherence_report/en/index.html."
"Social Science of Risk",22,"Tansey J and OâRiordan T (1999) Cultural theory and risk:  a review. Health, Risk & Society. 1 (1), 71â90."
"Social Science of Risk",23,"Mamadouh V (1999) Grid-group cultural theory: an introduction. GeoJournal. 47 (3), 395â409."
"Staphylococcus aureus: Dose Response Models",1,"Anonymous (2012) Foodborne Pathogenic Microorganisms and Natural Toxins Handbook Staphylococcus aureus, U.S. Food and Drug Administration."
"Staphylococcus aureus: Dose Response Models",2,"Anonymous (1999) Experimental Staph Vaccine Broadly Protective in Animal Studies, National Institute of Allergy and Infectious Diseases ,U.S. Department of Health and Human Services."
"Staphylococcus aureus: Dose Response Models",3,"Singh G, Marples RR, et al. (1971) EXPERIMENTAL STAPHYLOCOCCUS AUREUS INFECTIONS IN HUMANS. J Investig Dermatol 57(3): 149-162."
"Staphylococcus aureus: Dose Response Models",4,"Rose JB, Haas CN (1999) A risk assessment framework for the evaluation of skin infections and the potential impact of antibacterial soap washing. American Journal of Infection Control 27(6): S26-S33."
"Table of persistence models",1,"Kirk B (1985). Country gravy is bad for you. Journal of Meat Byproducts 67(3):293."
"Table of persistence models",2,"Yu U (1972). Survival of C. w. in sewage sludge. Sewage Sludge Quarterly 23(2):28."
TestPage,1,"Centers for Disease Control and Prevention (CDC) (2003) Emergency Preparedness and Response: Anthrax Q&A Signs and Symptoms [http://www.bt.cdc.gov/agent/anthrax/faq/signs.asp]"
TestPage,2,"Guidi-Rontani, C., Weber-Levy, M. Labruyere, E., Mock, M. (1999) Germination of ''Bacillus anthracis'' Spores Within Alveolar Macrophages. ''Molecular Microbiology'' '''31'''(1):9-17 [http://www.sciencedirect.com/science/article/pii/S0966842X02024228] "
TestPage,3,"Jernigan, J.A., Stephens, D.S., Ashford, D.A., Omenaca, C., Topiel, M.S>, Galbraith, M., Tapper, M., Zaki, S., Popovic, T., Meyer, R.F., Quinn, C.P., Harper, S.A., Fridkin, S.K., Sejvar, J.J., Shepard, C.W., McConnell, M., Guarner, J., Sheith, W-J., Malecki, J.M., Gerberding, J.L., Hughes, J.M., Perkins, B.A. (2001). Bioterrorism Related Inhalational Anthrax: The First 10 Cases Reported in the United States. Emerging Infectious Diseases. '''7'''(6): 933-944 "
TestPage,4,"Druett HA, Henderson DW, Packman L, Peacock S (1953) Studies on respiratory infection. I. The influence of particle size on respiratory infection with anthrax spores. Journal of Hygiene. 51: 359-371  [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2217739/pdf/jhyg00161-0069.pdf Full Text PDF via NIH]"
TestPage,5,"Altboum Z, Gozes Y, Barnea A, Pass A, White M, Kobiler D (2002) Postexposure prophylaxis against anthrax: Evaluation of various treatment regimes in intranasally infected guinea pigs Infection and Immunity 70(1): 6231-6241 [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC130326/ Full Text via PubMed]"
TestPage,6," Weir, M.H. (2009) Development of a Physiologically Based Pathogen Transport and Kinetics Model for the Inhalation of ''Bacillus anthracis'' Spores. Ph.D. Dissertation. Drexel University, Philadelphia PA [http://wiki.camra.msu.edu/images/b/bf/WeirM_2009_Dissertation.pdf] "
TestPage,7,"Weir, M.H. and Haas, C.N. (2011) A Model for In-vivo Delivered Dose Estimation for Inhaled ''Bacillus anthracis'' Spores in Humans with Interspecies Extrapolations. Environmental Science and Technology. '''45'''(13): 5828-5833 [http://pubs.acs.org/doi/abs/10.1021/es200901e] "
TestPage,8,"Weir, M.H. and Haas, C.N. (2011) A Model for In-vivo Delivered Dose Estimation for Inhaled ''Bacillus anthracis'' Spores in Humans with Interspecies Extrapolations. Environmental Science and Technology. '''45'''(13): 5828-5833 [http://pubs.acs.org/doi/abs/10.1021/es200901e] "
Tutorials,1,"[[Cryptosporidium parvum and Cryptosporidium hominis: Dose Response Models]]"
"Vibrio cholerae",1,"[http://emedicine.medscape.com/article/962643-overview#showall Medscape]"
"Vibrio cholerae",2,"[http://www.azdhs.gov/phs/edc/edrp/es/profcholera.htm Arizona Department of Health Services Cholera Page]"
"What is Risk Management",1,"NRC (National Research Council). 1983. Risk Assessment in the Federal Government: Managing the Process.Washington, DC: National Academy Press."
"What is Risk Management",2,"NRC (National Research Council) 2008. Science and Decisions: Advancing Risk Assessment. Washington DC. National Academy Press ."
"What is Risk Management",3,"NRC (National Research Council). 1983. Risk Assessment in the Federal Government: Managing the Process.Washington, DC: National Academy Press."
